

MARK NORMAN, Ph.D.

130 Venus St., Thousand Oaks, CA 91360 • 805.796.8257 • markn@sciconsolutions.com

PROFESSIONAL SUMMARY

Innovative and vision-driven Scientific Executive with over 35 years of success providing effective research, project management, solution development, and employee oversight in high-pressure environments. Conscientious professional with a distinctive legacy in the scientific world and a demonstrated history of effectively leading teams through new initiatives and program implementation. Committed to excellence; dedicated to maintaining a reputation built on quality, service, and uncompromising ethics.

AREAS OF EXPERTISE

- | | | |
|--------------------------------------|--|-------------------------------|
| ▪ Medicinal Chemistry/Drug Discovery | ▪ Cross-Functional Team Management | ▪ Staff Oversight & Mentoring |
| ▪ Project/Program Management | ▪ Complex Problem Resolution | ▪ Risk Assessment/Mitigation |
| ▪ Operations Streamlining | ▪ Safety Compliance/Adherence | ▪ Licensing Negotiations |
| ▪ Informatics Tool Creation | ▪ Procedure Development/Implementation | ▪ Conflict Management |
-

PROFESSIONAL EXPERIENCE

Scicon Solutions – Thousand Oaks, CA 2016 – present
President

Providing scientific consulting, medicinal chemistry support, and discovery research services to pharmaceutical and biotech companies and academia. Website: <https://sciconsolutions.com/>

BrainStorm Therapeutics, Inc. – San Diego, CA 2023 – present
Scientific Advisory Board

BrainStorm Therapeutics is a biotechnology company developing a proprietary "human-first" CNS drug discovery platform utilizing patient iPSC-derived models of brain disease to discover molecules that restore synaptic network function and halt, prevent, or reverse neurodegeneration. Website: <https://www.brainstormtherapeutics.org/>

ADRx Pharmaceuticals, Inc. – Thousand Oaks, CA 2020 – present
Scientific Advisory Board

Guiding ADRx's scientific team in their efforts to develop a unique approach to halting diseases of protein aggregation by utilizing structural insights of aggregated proteins in the form of amyloid and biomolecular condensates. Website: <https://www.adrxpharma.com/>

California Lutheran University – Thousand Oaks, CA 2016 – 2018
Adjunct Chemistry Professor

Taught undergraduate organic chemistry.

Amgen, Inc. – Thousand Oaks, CA 1996 – 2015
Scientific Executive Director (2011 – 2015)

Director of Research (2006 – 2011)

Associate Director of Research II (2004 – 2006)

Provided effective chemistry research team and project leadership several drug discovery projects, from initial hit identification to clinical trials in the areas of oncology, inflammation, metabolic disorders, and neuroscience.

- Acted as Medicinal Chemistry Leader, Co-Manager, or Project Team Leader for multiple initiatives including: PI3K α , c-Met, B-Raf, TRPM8, and GKRPs drug discovery programs leading to clinical candidates: AMG 511, 208, 458, 337, 333, and 339, which progressed into clinical trials for the treatment of cancer, pain, and migraine.

- Personally authored and published several high-impact research publications some of which were utilized in external training programs (Drew University School of Medicinal Chemistry and Gordon Research Conference).
- Key contributor to informatics tool development for the department; designed a MyTeams site for Medicinal Chemistry Department, which helped to significantly enhance the staff's productivity.
- Team Lead for several drug discovery projects such as TRPV1, CDK5, B1, PTP1B, NPY5, CB1, and MC4 research programs; Directed medicinal chemistry efforts aimed at identifying clinical candidates for the treatment of stroke, pain, diabetes, obesity, and Parkinson's disease that lead to: AMG 517, 628, and 474.
- Discovery Research Leader and Program Manager for Amgen's B14/B29 building consolidation project supporting Amgen's Full Potential Geographic Footprint Initiative. Acted as key point of accountability with multiple internal and external organizations, architects, contractors, and equipment specialists, and provided strategic direction for reorganization and consolidation efforts.
- Served as Site Head for Environmental Health Safety & Sustainability/EHSS for the 435K sq. ft. Thousand Oaks B29 site housing 490 full-time personnel. Set site safety goals, scheduled appropriate safety training, established metrics reporting and risk assessment plans, conducted regular laboratory inspections, and set overall tone for safe practices.
- Led a cross-functional Site-Safety team comprised of 45 members; Served on the core team of the R&D Safety Improvement Plan: Safe Laboratory Practices and Safety Culture leading to significantly fewer accidents and injuries from the previous year.
- Successfully led the \$2.5M cross-site electronic notebook, "e-Notebook" project initiative; collaborated with the Research Informatics group and an outside vendor to design, deploy, and implement an efficient electronic notebook system for the entire Medicinal Chemistry Department, thereby completely eliminating paper notebooks and providing the chemists and patent attorneys a valuable, real-time, searchable database.

Additional significant contributions include:

- » Contributed to the identification of eleven clinical candidates.
- » Distinction of holding more Amgen patents than any other employee and for being one of the most published authors in the company's cumulative history.
- » First Scientist featured on Amgen's R&D website.
- » Requested by upper management to evaluate licensing opportunities focused on the treatment of head trauma, stroke, obesity, epilepsy, diabetes, arrhythmia, cancer, inflammation, and pain; performed extensive analyses and made appropriate recommendations to senior management. Efforts led to the in-licensing of a promising series of compounds for the treatment of inflammatory conditions.
- » Client sponsor for Chemistry's Research Informatics projects that included the successful development of a new compound registration system (CoRe) and the Retire ISIS Project (RIP). The compound registration system was integrated with the electronic notebook system saving time and streamlining the chemist's workflow.
- » Member of BACE Medicinal Chemistry Team that recently identified 2 clinical candidates, AMG 978 & AMG 138.
- » Member of the Research Management Committee/RMC for the BioFocus collaboration.
- » Medicinal Chemistry Chairman; coordinated internal/external speaker presentations for departmental meetings.
- » Accountable for overseeing teams and introducing effective learning courses and project initiatives for department.
- » Introduced courses such as "Scientific & Technical Writing" that improved the employee skill sets within the Medicinal Chemistry Division.

Additional Relevant Positions

Amgen • Research Scientist II, Research Scientist III, and Associate Director of Research I	1996 – 2004
Glaxo Wellcome, Inc. • Senior Research Investigator	1995 – 1996
Burroughs Wellcome Co. • Research Scientist III, Research Scientist IV, and Research Scientist V	1987 – 1995

University of California, Berkeley • Research Assistant	1982 – 1987
Alfa Products, Thiokol/Ventron Division • Synthetic Organic Chemist	1982
University of New Hampshire (Chemical Engineering Department) • Analytical Chemist	1981

EDUCATION

Ph.D. Organic Chemistry • GPA 3.98/4.00 • University of California, Berkeley

B.S. Chemistry • GPA 3.71/4.00; Summa cum Laude • University of New Hampshire

PROFESSIONAL AFFILIATIONS

Associate Editor • *The Journal of Pharmacognosy*

Editorial Advisory Board • *Pharmaceuticals • Medicinal Chemistry Reviews • Current Topics in Medicinal Chemistry • Medicinal Chemistry-Online • The Open Drug Discovery Journal • Journal of International Research in Medical & Pharmaceutical Sciences*

Referee • *Journal of Medicinal Chemistry • Bioorganic & Medicinal Chemistry Letters • Journal of Organic Chemistry • Journal of Heterocyclic Chemistry • Medicinal Chemistry*

Member • American Chemical Society

HONORS AND AWARDS

- | | | |
|--|--|--|
| ▪ Amgen Discovery Research Innovation Award | ▪ Burroughs Wellcome Co. Excellence and Special Performance Awards | ▪ Phi Kappa Phi Honor Society |
| ▪ Journal of Medicinal Chemistry Highly Read Article Award | ▪ Marquis Who's Who in Medicine and Healthcare | ▪ Bailey Prize in Chemistry |
| ▪ Featured scientist profiled for Amgen's R&D website | ▪ Sigma Xi Scientific Research Society | ▪ Richard M. Ford Memorial Award |
| ▪ Amgen Star and Bravo Awards (17x) | ▪ Bruce H. Mahan Memorial Teaching Award | ▪ Heman C. Fogg Fellowship in Analytical Chemistry |
| ▪ Bioorganic & Medicinal Chemistry Letters: Most Cited Paper Award | ▪ Phi Lambda Upsilon Honor Society | ▪ Sophomore Award in Organic Chemistry |
| ▪ Amgen Special Recognition Award | ▪ Phi Beta Kappa Honor Society | ▪ High School Valedictorian |
-

PUBLICATIONS/PRESENTATIONS/PATENTS (See Appendix for a detailed reference list)

81 • Publications in peer-reviewed journals

1 • Book Chapter

89 • Presentations


67 • Patents

VOLUNTEER & COMMUNITY SERVICE

Alzheimer's Association • Conejo Parks & Recreation • Habitat for Humanity • Manna Conejo Valley Food Distribution Center • American Cancer Society • Tushita Kadampa Buddhist Center • Children's Hospital LA International Medical Corps • Arthritis Foundation • Leukemia & Lymphoma Society, Inc. • Wells Bring Hope

APPENDIX

PUBLICATIONS



1. Clayton H. Heathcock, Mark H. Norman, and David E. Uehling, "Stereoselection in the Michael Addition Reaction. 1. The Mukaiyama-Michael Reaction" *Journal of the American Chemical Society*, **1985**, 107(9), 2747-2799.
2. Mark H. Norman and Clayton H. Heathcock, "Novel Transformations Leading to 3-Benzylindolizidin-2-one" *Journal of Organic Chemistry*, **1987**, 52(2), 226-235.
3. Mark H. Norman and Clayton H. Heathcock, "Improved Synthesis of N-Benzyl-5-ethyl-1,2,3,4-tetrahydropyridine" *Journal of Organic Chemistry*, **1988**, 53(14), 3370-3371.
4. Clayton H. Heathcock, Mark H. Norman, and Daniel A. Dickman, "Total Synthesis of (+/-)-Vallesamidine" *Journal of Organic Chemistry*, **1990**, 55(3), 798-811.

5. Mark H. Norman, Merrick R. Almond, Barbara E. Reitter, and S. George Rahim, "Novel Synthesis of (+/-)-cis-4-Amino-2-cyclopentene-1-methanol, a Key Intermediate in the Preparation of Carbocyclic 2',3'-Didehydro-2',3'-dideoxy Nucleosides" *Synthetic Communications*, **1992**, 22(22), 3197-3204.
6. Mark H. Norman, Douglas J. Minick, and Gary E. Martin, "Structural Elucidation of an Oxazolo[5,4-b]pyridine: An Alternative Cyclization Product Related to Nevirapine" *Journal of Heterocyclic Chemistry*, **1992**, 30(3), 771-779.
7. Mark H. Norman, James L. Kelley, and Elizabeth B. Hollingsworth, "Conformationally Restricted Analogues of Remoxipride as Potential Antipsychotic Agents" *Journal of Medicinal Chemistry*, **1993**, 36(22), 3417-3423.
8. Mark H. Norman, Greg C. Rigdon, Frank Navas III, and Barrett R. Cooper, "Cyclic Benzamides as Mixed Dopamine D₂/Serotonin 5-HT₂ Receptor Antagonists: Potential Atypical Antipsychotic Agents" *Journal of Medicinal Chemistry*, **1994**, 37(16), 2552-2563.
9. David K. Stammers, D. O'N. Somers, C. K. Ross, I. Kirby, P. H. Ray, J. E. Wilson, Mark H. Norman, J. S. Ren, R. M. Esnouf, E. F. Garman, E. Y. Jones and D. I. Stuart, "Crystals of HIV-1 Reverse Transcriptase Diffracting to 2.2Å Resolution" *Journal of Molecular Biology*, **1994**, 242, 586-588.
10. Michael J. Durcan, Greg C. Rigdon, Philip F. Morgan, and Mark H. Norman, "Is Clozapine Selective for the Dopamine D₄ Receptor?" *Life Sciences, Pharmacology Lett.*, **1995**, 57(18), 275-283.
11. Mark H. Norman, H. David Smith, C. Webster Andrews, Flora L. M. Tang, Conrad L. Cowan, and Robert P. Steffen, "4-(Heteroarylthio)-2-biphenyltetrazoles as Nonpeptide Angiotensin II Antagonists" *Journal of Medicinal Chemistry*, **1995**, 38, 4670-4678.
12. Mark H. Norman, Douglas J. Minick, and Greg C. Rigdon, "Effect of Linking Group Modifications on the Antipsychotic Profile of Some Phthalimide and Isoindolinone Derivatives" *Journal of Medicinal Chemistry*, **1996**, 39, 149-157.
13. Greg C. Rigdon, Gerald Pollard, Virginia Boncek, Walter Faison, Mark H. Norman, and James Howard, "1192U90 in Animal Tests That Predict Antipsychotic Efficacy and Extrapyramidal Side Effects" *Neuropharmacology*, **1996**, 15, 231-242.
14. Mark H. Norman, Greg C. Rigdon, Frank Navas III, and William Hall, "Structure-Activity Relationships within a Series of Substituted Benzamides: Potent D₂/5-HT₂ Antagonists as Neuroleptic Agents" *Journal of Medicinal Chemistry*, **1996**, 39, 1172-88.
15. Frank Navas III and Mark H. Norman, "The Design and Synthesis of a Hapten for 1192U90: A Potential Atypical Antipsychotic Agent" *Synthetic Communications*, **1996**, 26, 1411-1421.
16. Mark H. Norman and Stephen D. Gabriel, "Synthesis of ¹³C- and ¹⁴C-labeled 1192U90, an ortho-Amino Benzamide with a Preclinical Atypical Antipsychotic Profile" *Journal of Labelled Compounds and Radiopharmaceuticals*, **1996**, 38, 269-280.

17. Mark H. Norman, Frank Navas III, James Thompson, and Greg C. Rigdon, "Synthesis and Evaluation of Heterocyclic Carboxamides as Potential Atypical Antipsychotic Agents" *Journal of Medicinal Chemistry*, **1996**, 39, 4692-4703.
18. Douglas J. Minick and Mark H. Norman, "An IR Investigation of Intramolecular Hydrogen Bonding in a Set of N, N'-Disubstituted Piperazine Hydrochlorides" Submitted to the *Journal of Molecular Structure*, **1997**.
19. Frank Navas III, Flora L. M. Tang, Lee Schaller and Mark H. Norman, "Analogues of the Potential Antipsychotic Agent 1192U90: Amide Modifications" *Journal of Bioorganic & Medicinal Chemistry*, **1998**, 6, 811-823.
20. Ning Chen, Yuelie Lu, Kumar Gadamasetti, Clarence R. Hurt, Mark H. Norman and Christopher Fotsch, "A Short, Facile Synthesis of 3-Amino-2-carboxy-5-substituted Pyrroles" *Journal of Organic Chemistry*, **2000**, 65, 2603-2605.
21. Anthony W. Bannon, Jennifer. Seda, Michelle Carmouche, J. M. Francis, Mark H. Norman, William Karbon and Michael L. McCaleb, "Behavioral Characterization of Neuropeptide Y Knockout Mice" *Brain Research*, **2000**, 868, 79-87.
22. Mark H. Norman, Ning Chen, Zhidong Chen, Chris Fotsch, Ray Hurt, Clarence Hale, Bruce Han, Tracy Jenkins, John Kincaid, Longbin Liu, Yuelie Lu, Ofir Moreno, Vincent Santora, Jennifer D. Sonnenberg, and William Karbon, "Structure-Activity Relationships of a Series of Deazapurines as NPY-5 Receptor Antagonists" *Journal of Medicinal Chemistry*, **2000**, 43(22), 4288-4312.
23. Christopher Fotsch, Jennifer D. Sonnenberg, Ning Chen, Clarence Hale, William Karbon, and Mark H. Norman, "Structure-Activity Relationships of Trisubstituted Phenyl Urea Derivatives as NPY-5 Receptor Antagonists" *Journal of Medicinal Chemistry*, **2001**, 44(14), 2344-2356.
24. Premilla Arasasingham, Chris Fotsch, Xiaohu Ouyang, Mark H. Norman, Michael G. Kelly, Kevin L. Stark, William Karbon, Clarence hale, Jamie Baumgartner, Martha Zambrano, and Nuria A. Tamayo, "SAR of (1-Aryl-2-piperazinylethyl)piperazines: Antagonists for the AGRP/Melanocortin Receptor Binding" *Journal of Medicinal Chemistry*, **2003**, 46(1), 9-11.
25. Samuel W. Gerritz, Mark H. Norman, Judd Berman, Eric Bigham, Michael J. Bishop, Deanna E. Garrison, Dennis Heyer, Steven J. Hodson, James Linn, Brian E. Marron, Suganthini S. Nanthakumar, and Frank Navas, "High Throughput Manual Parallel Synthesis using Mimotopes SynPhaseTM Crowns" *Journal of Combinatorial Chemistry*, **2003**, 5(2), 110-117.
26. Christopher Fotsch, Duncan M. Smith, Jeffrey A. Adams, Janet Cheetham, Michael Croghan, Elizabeth M. Doherty, Clarence Hale, Mark A. Jarosinski, Michael G. Kelly, Mark H. Norman, Nuria A. Tamayo, Ning Xi, and James W. Baumgartner, "Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-dPhe-Arg-Trp-Lys]-NH₂" *Bioorganic & Medicinal Chemistry Letters* **2003**, 13(14), 2337-2340.

27. Ning Xi, Clarence Hale, Michael G. Kelly, Mark H. Norman, Markian Stec, Shimin Xu, Baumgartner, and Chris Fotsch, "Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core" *Bioorganic & Medicinal Chemistry Letters* **2004**, 14(2), 377-381.
28. Elizabeth M. Doherty, Christopher Fotsch, Yunxin Bo, Partha P. Chakrabarti, Ning; Chen, Narender Gavva, Nianhe Han, Michael G. Kelly, John Kincaid, Lana Klionsky, Qingyian Liu, Vassil I. Ognyanov, Rami Tamir, Xianghong Wang, Jiawang Zhu, Mark H. Norman, and James J. S. Treanor, "Discovery of Potent, Orally Available Vanilloid Receptor-1 Antagonists. Structure-Activity Relationship of N-Aryl Cinnamides" *Journal of Medicinal Chemistry* **2005**, 48(1), 71-90.
29. Narender R. Gavva, Rami Tamir, Yusheng Qu, Lana Klionsky, T.J. Zhang, Joe Ligutti, David Immke, Judy Wang, Dawn Zhu, Di Bian, Steve Edenson, Jack D. Lile, Todd W. Vanderah, Frank Porreca, Elizabeth M. Doherty, Mark H. Norman, Ken W. Wild, Anthony W. Bannon, Jean-Claude Louis, and James J. S. Treanor, "AMG 9810, (2E)-N-(2H, 3H-benzo[e]1,4-dioxan-6-yl)-3-[4-(t-butyl)phenyl]prop-2-enamide a novel vanilloid receptor 1 (TRPV1) antagonist with analgesic properties" *Journal of Pharmacology and Experimental Therapeutics* **2004**, 313(1), 474-484.
30. Christopher Fotsch, Nianhe Han, Premilla Arasasingham, Yunxin Bo, Michelle Carmouche, Ning Chen, James Davis, Martin H. Goldberg, Clarence Hale, Feng-Yin Hsieh, Michael G.; Kelly, Qingyian Liu, Mark H. Norman, Duncan M. Smith, Markian Stec, Nuria Tamayo, Ning Xi, Shimin Xu, Anthony W. Bannon, and James W. Baumgartner, "Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides" *Bioorganic & Medicinal Chemistry Letters* **2005**, 15(6), 1623-1627.
31. Ning Xi, Yunxin Bo, Elizabeth M. Doherty, Christopher Fotsch, Narender R. Gavva, Nianhe Han, Randall W Hungate, Lana Klionsky, Qingyian Liu, Rami Tamir, Shimin Xu, James J. S. Treanor, and Mark H. Norman, "Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists" *Bioorganic & Medicinal Chemistry Letters* **2005**, 15(23), 5211-5217.
32. Narender R. Gavva, Rami Tamir, Lana Klionsky, Mark H. Norman, Jean-Claude Louis, Kenneth D. Wild, and James J. S. Treanor, "Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1" *Molecular Pharmacology* **2005**, 68(6), 1524-1533.
32. Ognyanov, V. I.; Balan, C.; Bannon, A.W.; Bo, Y.; Dominguez, C.; Fotsch, C.; Gore, V. K.; Klionsky, L.; Ma, V. M.; Qian, Y-X; Tamir, R. Wang, X.; Xi, N.; Xu, S.; Zhu, D.; Gavva, N. R.; Treanor, J. J. S.; Norman, M. H. "Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1 (TRPV1). Structure-Activity Relationships of 2-(Piperazin-1-yl)-1H-benzimidazoles" *Journal of Medicinal Chemistry* **2006**, 49, 3719-3742.
33. D'Amico, Derin C.; Aya, Toshi; Human, Jason; Fotsch, Christopher; Chen, Jian Jeffrey; Biswas, Kaustav; Riahi, Bobby; Norman, Mark H.; Willoughby, Christopher A.; Hungate, Randall; Reider, Paul J.; Biddlecome, Gloria; Lester-Zeiner, Dianna; Van Staden, Carlo; Johnson, Eileen; Kamassah, Augustus; Arik, Leyla; Wang, Judy; Viswanadhan, Vellarkad N.; Groneberg, Robert D.; Zhan, James; Suzuki, Hideo; Toro, Andras; Mareska, David A.; Clarke, David E.; Harvey, Darren M.; Burgess, Laurence E.; Laird, Ellen R.; Askew, Benny; Ng, Gordon. "Identification of a Nonpeptidic and Conformationally Restricted

Bradykinin B1 Receptor Antagonist with Anti-Inflammatory Activity” *Journal of Medicinal Chemistry* **2007**, 50(4), 607-610.

34. Gavva, Narender R.; Bannon, Anthony W.; Surapaneni, Sekhar; Hovland, David N., Jr.; Lehto, Sonya G.; Gore, Anu; Juan, Todd; Deng, Hong; Han, Bora; Kliensky, Lana; Kuang, Rongzhen; Le, April; Tamir, Rami; Wang, Jue; Youngblood, Brad; Zhu, Dawn; Norman, Mark H.; Magal, Ella; Treanor, James J. S.; Louis, Jean-Claude. “The Vanilloid Receptor TRPV1 is Tonicly Activated In Vivo and Involved in Body Temperature Regulation” *Journal of Neuroscience* **2007**, 27(13), 3366-3374.

35. Biswas, Kaustav; Li, Aiwen; Chen, Jian Jeffrey; D'Amico, Derin C.; Fotsch, Christopher; Han, Nianhe; Human, Jason; Liu, Qingyan; Norman, Mark H.; Riahi, Bobby; Yuan, Chester; Suzuki, Hideo; Mareska, David A.; Zhan, James; Clarke, David E.; Toro, Andras; Groneberg, Robert D.; Burgess, Laurence E.; Lester-Zeiner, Dianna; Biddlecome, Gloria; Manning, Barton H.; Arik, Leyla; Dong, Hong; Huang, Ming; Kamassah, Augustus; Loeloff, Richard; Sun, Hong; Hsieh, Feng-Yin; Kumar, Gondi; Ng, Gordon Y.; Hungate, Randall W.; Askew, Benny C.; Johnson, Eileen. “Potent Nonpeptide Antagonists of the Bradykinin B1 Receptor: Structure-Activity Relationship Studies with Novel Diaminochroman Carboxamides” *Journal of Medicinal Chemistry* **2007**, 50(9), 2200-2212.

36. Norman, Mark H.; Zhu, Jiawang; Fotsch, Christopher; Bo, Yunxin; Chen, Ning; Chakrabarti, Partha; Doherty, Elizabeth M.; Gavva, Narender R.; Nishimura, Nobuko; Nixey, Thomas; Ognyanov, Vassil I.; Rzasa, Robert M.; Stec, Markian; Surapaneni, Sekhar; Tamir, Rami; Viswanadhan, Vellarkad N.; Treanor, James J. S. “Novel Vanilloid Receptor-1 Antagonists: 1. Conformationally Restricted Analogues of trans-Cinnamides” *Journal of Medicinal Chemistry* **2007**, 50(15), 3497-3514.

37. Doherty, Elizabeth M.; Fotsch, Christopher; Bannon, Anthony W.; Bo, Yunxin; Chen, Ning; Dominguez, Celia; Falsey, James; Gavva, Narender R.; Katon, Jodie; Nixey, Thomas; Ognyanov, Vassil I.; Pettus, Liping; Rzasa, Robert M.; Stec, Markian; Surapaneni, Sekhar; Tamir, Rami; Zhu, Jiawang; Treanor, James J. S.; Norman, Mark H.. “Novel Vanilloid Receptor-1 Antagonists: 2. Structure-Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate” *Journal of Medicinal Chemistry* **2007**, 50(15), 3515-3527.

38. Wang, Hui-Ling; Katon, Jodie; Balan, Chenera; Bannon, Anthony W.; Bernard, Charles; Doherty, Elizabeth M.; Dominguez, Celia; Gavva, Narender R.; Gore, Vijay; Ma, Vu; Nishimura, Nobuko; Surapaneni, Sekhar; Tang, Phi; Tamir, Rami; Thiel, Oliver; Treanor, James J. S.; Norman, Mark H.. “Novel Vanilloid Receptor-1 Antagonists: 3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties” *Journal of Medicinal Chemistry* **2007**, 50(15), 3528-3539.

39. Alexandre A. Steiner, Victoria F. Turek, Maria C. Almeida, Jeffrey J. Burmeister, Daniela L. Oliveira, Jennifer L. Roberts, Anthony W. Bannon, Mark H. Norman, Jean-Claude Louis, James J. S. Treanor, Narender R. Gavva, and Andrej A. Romanovsky “**Nonthermal Activation of Transient Receptor Potential Vanilloid-1 Channels in Abdominal Viscera Tonicly Inhibits Autonomic Cold-Defense Effectors**” *Journal of Neuroscience* **2007**, (27), 7459–7468.

40. Robert M. Rzasa, Matthew Kaller, Gang Liu, Ella Magal, Thomas Nguyen, Timothy D. Osslund, David Powers, Vincent J. Santora, Hui-Ling Wang, Xiaoling Xiong, Wenge Zhong, and Mark H. Norman

“Structure-Activity Relationships of 3,4-Dihydro-1H-quinazolin-2-one Derivatives as Potential CDK5 Inhibitors” *Bioorganic & Medicinal Chemistry* **2007**, (15), 6574-6595.

41. Narender R. Gavva, Anthony W. Bannon, David Hovland Jr., Sonya Lehto, Lana Klionsky, Sekhar Surapaneni, David C. Immke, Charles Henley, Leyla Arik, Annette Bak, James Davis, Nadia Ernst, Gal Hever, Rongzhen Kuang, Licheng Shi, Rami Tamir, Jue Wang, Weiya Wang, Gary Zajic, Dawn Zhu, Mark H. Norman, Jean-Claude Louis, Ella Magal, and James J. S. Treanor “Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade” *Journal of Pharmacology and Experimental Therapeutics*, **2007** (323), 128-137.

42. Wenge Zhong, Hu Liu, Matthew Kaller, Ella Magal, Thomas Nguyen, Timothy D. Osslund, David Powers, Robert M. Rzasa, Hui-Ling Wang, Xiaoling Xiong, Jiandong Zhang, and Mark H. Norman. “Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors” *Bioorganic & Medicinal Chemistry Letters*, **2007**, (17) 5384-5389.

43. Vijay K. Gore, Vu V. Ma, Rami Tamir, Narender R. Gavva, James J. S. Treanor, and Mark H. Norman “Structure-Activity Relationship (SAR) Investigations of Substituted Imidazole Analogs as TRPV1 Antagonists” *Bioorganic & Medicinal Chemistry Letters*, **2007**, (17) 5825-5830.

44. Vellarkad N. Viswanadhan, Yaxiong Sun, and Mark H. Norman “Three Dimensional Quantitative Structure-Activity Relationships (3D-QSARs) and activity predictions of human TRPV1 channel antagonists: Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA) of Cinnamides” *Journal of Medicinal Chemistry* **2007**, 500, 5608-5619.

45. Xianghong Wang, Partha P. Chakrabarti, Vassil I. Ognyanov, Liping H. Pettus, Rami Tamir, Helming Tan, Phi Tang, James J. S. Treanor, Narender R. Gavva, and Mark H. Norman “Trisubstituted Pyrimidines as Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists with Improved Solubility” *Bioorganic & Medicinal Chemistry Letters*, **2007**, 17, 6539-6545.

46. Elizabeth M. Doherty Daniel Retz, Narender R. Gavva, Rami Tamir, James J. S. Treanor, and Mark H. Norman “4-Aminopyrimidine Tetrahydronaphthols: A Series of Novel Vanilloid Receptor-1 Antagonists with Improved Solubility and Pharmacokinetic Properties” *Bioorganic & Medicinal Chemistry Letters*, **2008**, 18, 1830-1834.

47. Nuria Tamayo, Hongyu Liao, Markian M. Stec, Xianghong Wang, Partha Chakrabarti, Dan Retz, Elizabeth M. Doherty, Sekhar Surapaneni, Rami Tamir,[#] Anthony W. Bannon, Narender R. Gavva, and Mark H. Norman “The Design and Synthesis of Peripherally Restricted Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists” *Journal of Medicinal Chemistry* **2008**, 51, 2744-2757.

48. Narender R. Gavva, Andras Garami, Liang Fang, Sekhar Surapaneni, Anna Akrami, Francisco Alvarez, Annette Bak, Mary Darling, Anu Gore, Graham R. Jang, Patrick Kesslak, Liyun Ni, Mark H. Norman, Gabrielle Palluconi, Mark J. Rose, Margaret Salfi, Edward Tan, James J. S. Treanor, Andrej Romanovsky, Christopher Banfield, and Gudarz Davar “Pharmacological Blockade of the Vanilloid Receptor TRPV1 Elicits Marked Hyperthermia in Humans” *Pain*, **2008**, 136, 202-210.

49. Cowper-Smith, C.D.; Anger, G.J.; Magal, E. Norman, M.H. and Robertson, G.S. Delayed Administration of a Potent CDK and GSK3 β Inhibitor Produces Long-term Neuroprotection in a Hypoxia-ischemia Model of Brain Injury *Neuroscience* **2008**, 155 (3), 864-875.
50. Lehto, Sonya G.; Tamir, Rami; Deng, Hong; Klionsky, Lana; Kuang, Rongzhen; Le, April; Lee, Doo; Louis, Jean-Claude; Magal, Ella; Manning, Barton H.; Rubino, John; Surapaneni, Sekhar; Tamayo, Nuria; Wang, Tingrong; Wang, Judy; Wang, Jue; Wang, Weiya; Youngblood, Brad; Zhang, Maosheng; Zhu, Dawn; Norman, Mark H.; Gavva, Narendra R. “Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats” *Journal of Pharmacology and Experimental Therapeutics* **2008**, 326 (1), 218-229.
51. Liu, Longbin; Siegmund, Aaron; Xi, Ning; Kaplan-Lefko, Paula; Rex, Karen; Chen, April; Lin, Jasmine; Moriguchi, Jodi; Berry, Loren; Huang, Liyue; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Bellon, Steven F.; Lee, Matthew; Shimanovich, Roman; Bak, Annette; Dominguez, Celia; Norman, Mark H.; Harmange, Jean-Christophe; Dussault, Isabelle; Kim, Tae-Seong. “Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)” *Journal of Medicinal Chemistry* **2008**, 51(13), 3688-3691.
52. Markian M. Stec, Yunxin Bo, Partha P. Chakrabarti, Lillian Liao, Mqhele Ncube, Nuria Tamayo, Rami Tamir, Narendra R. Gavva, James J. S. Treanor, and Mark H. Norman “Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists” *Bioorganic & Medicinal Chemistry Letters*, **2008**, 18, 5118-5122.
53. Andrej A. Romanovsky, Maria C. Almeida; Andras Garami; Alexandre A. Steiner, Mark H. Norman, Shaun F. Morrison; Kazuhiro Nakamura, Jeffrey J. Burmeister, and Tatiane B. Nucci “The Transient Receptor Potential Vanilloid-1 Channel in Thermoregulation: A Thermosensor it is Not.” *Pharmacological Rev*, **2009**, 61, 228-261.
54. Matthew R. Kaller, Wenge Zhong, Charles Henley, Ella Magal, Thomas Nguyen, Timothy D. Osslund, David Powers, Robert M. Rzasa, Weiya Wang, Xiaoling Xiong, Jiandong Zhang, and Mark H. Norman, “Design and Synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors” *Bioorganic & Medicinal Chemistry Letters* **2009**, 19, 6591-6594.
55. Vijay K. Gore, Vu V. Ma, Elizabeth M. Doherty, David Immke, Joe Ligutti, Ruoyuan Yin, Anruo Zou, and Mark H. Norman, “Structure activity relationship (SAR) investigations of tetrahydroquinolines as BKCa agonists.” *Bioorganic & Medicinal Chemistry Letters* **2010**, 20, 3573-3578.
56. Mark H. Norman, “The Discovery of TRPV1 Antagonists: Turning up the Heat” Invited book chapter for new book series entitled “*Accounts in Drug Discovery*” DOI: 10.1039/9781849731980; Joel Barrish (Editor), Percy Carter (Editor), Robert Zahler (Editor); **ISBN (online):** 978-1-84973-198-0; **ISBN (print):** 978-1-84973-126-3; pg 287-315. **Copyright: 2011.**
57. Noel D. D’Angelo, Tae-Seong Kim, Kristin Andrews, Shon K. Booker, Sean Caenepeel, Kui Chen, Derin D’Amico, Dan Freeman, Jian Jiang, Longbin Liu, John D. McCarter, Tisha San Miguel, Erin L. Mullady, Michael Schrag, Raju Subramanian, Jin Tang, O Robert C. Wahl, Ling Wang, Douglas A. Whittington, Tian Wu, Ning Xi, Yang Xu, Peter Yakowec, Kevin Yang, Leeanne P. Zalameda, Nancy Zhang, Paul Hughes, and Mark H. Norman “Discovery and Optimization of a Series of Benzothiazole

Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors” *Journal of Medicinal Chemistry*, **2011**, 54, 1789–1811.

58. Nobuko Nishimura, Aaron Siegmund, Longbin Liu, Kevin Yang, Marian C. Bryan, Kristin L. Andrews, Yunxin Bo, Shon K. Booker, Sean Caenepeel, Daniel Freeman, Hongyu Liao, John McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Nuria Tamayo, Ling Wang, Douglas A. Whittington, Leeanne Zalameda, Nancy Zhang, Paul E. Hughes, and Mark H. Norman “Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and StructureActivity Relationships of a Series of Quinoline and Quinoxaline Derivatives” *Journal of Medicinal Chemistry*, **2011**, 54, 4735–4751.

59. Markian M. Stec, Kristin L. Andrews, Shon K. Booker, Sean Caenepeel, Daniel J. Freeman, Jian Jiang, Hongyu Liao, John McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Nuria Tamayo, Ling Wang, Kevin Yang, Leeanne P. Zalameda, Nancy Zhang, Paul E. Hughes, and Mark H. Norman “Structure Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors:Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability” *Journal of Medicinal Chemistry*, **2011**, 54, 5174–5184.

60. Nuria A. Tamayo, Yunxin Bo, Vijay Gore, Vu Ma, Nobuko Nishimura, Phi Tang, Sonia Letho, Narender R. Gavva, and Mark H. Norman “Fused Piperidines as a Novel Class of Potent and Orally Available TRPM8 Antagonists for the Treatment of Pain” *Journal of Medicinal Chemistry*, **2012**, 55, 1593–1611.

61. Mark H. Norman, Longbin Liu, Matthew Lee, Ning Xi, Ingrid Fellows, Noel D. D'Angelo, Celia Dominguez, Karen Rex, Steven F. Bellon, Tae-Seong Kim, and Isabelle Dussault “Structure-based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives” *Journal of Medicinal Chemistry*, **2012**, 55, 1858–1867.

62. Longbin Liu, Mark H. Norman, Matthew Lee, Ning Xi, Aaron Siegmund, Alessandro Boezio, Shon Booker, Debbie Choquette, Noel D. D'Angelo, Julie Germain, Kevin Yang, Steven F. Bellon, Douglas A. Whittington, Jean-Christophe Harmange, Celia Dominguez, Tae-Seong Kim, and Isabelle Dussault “Structure-based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series” *Journal of Medicinal Chemistry*, **2012**, 55, 1868–1897.

63. Adrian L. Smith, Yunxin Bo, Noel D'Angelo, Brad Herberich, Fang-Tsao Hong, Claire Jackson, Nuria Tamayo, Liping Pettus, Ryan Wurz, Kristin Andrews, Douglas A. Whittington, John D. McCarter, Tisha San Miguel, Robert C. Wahl, Raju Subramanian, Ling Wang, Sean Caenepeel, Paul Hughes, and Mark H. Norman “Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases” *Journal of Medicinal Chemistry*, **2012**, 55, 5188–5219.

64. Ryan P. Wurz, Longbin Liu, Kevin Yang, Nobuko Nishimura, Yunxin Bo, Liping H. Pettus, Sean Caenepeel, Daniel J. Freeman, John D. McCarter, Erin L. Mullady, Tisha San Miguel, Ling Wang, Nancy Zhang, Kristin L. Andrews, Douglas A. Whittington, Jian Jiang, Raju Subramanian, Paul E. Hughes, and Mark H. Norman “Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold” *Bioorganic & Medicinal Chemistry Letters* **2012**, 22, 5714-5720.

65. Mark H. Norman, Kristin L. Andrews, Yunxin Y. Bo, Shon K. Booker, Sean Caenepeel, Victor J. Cee, Noel D. D'Angelo, Daniel J. Freeman, Bradley J. Herberich, Fang-Tsao Hong, Claire L. M. Jackson, Jian Jiang, Brian A. Lanman, Longbin Liu, John D. McCarter, Erin L. Mullady, Nobuko Nishimura, Liping H. Pettus, Anthony B. Reed, Tisha San Miguel, Adrian L. Smith, Seifu Tadesse, Andrew Tasker, Divesh Aidasani, Sean Zhu, Raju Subramanian, Nuria A. Tamayo, Ling Wang, Douglas A. Whittington, Bin Wu, Tian Wu, Ryan P. Wurz, Kevin Yang, Leeanne Zalameda, Nancy Zhang, and Paul E. Hughes "Selective Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors: Optimization of a Series of Pyridyl-triazines Leading to the Identification of a Clinical Candidate" *Journal of Medicinal Chemistry*, **2012**, 55(17), 7796-7816.

66. Lloyd, D. J.; St. Jean, D. J., Jr.; Kurzeja, R. J. M.; Wahl, R. C.; Michelsen, K.; Cupples, R.; Chen, M.; Wu, J.; Sivits, G.; Helmering, J.; Ashton, K. S.; Pennington, L. D.; Fotsch, C. H.; Vazir, M.; Chen, K.; Chmait, S.; Zhang, J.; Liu, L.; Norman, M. H.; Andrews, K. A.; Bartberger, M. D.; Van, G.; Galbreath, E. J.; Vonderfecht, S. L.; Wang, M.; Jordan, S. R.; Véniant, M. M.; Hale, C. "Anti-Diabetic Effects of a Glucokinase Regulatory Protein Small Molecule Disruptors" *Nature*, **2013**, 504(7480), 437-440.

67. St. Jean, D. J., Jr.; Ashton, K. S.; Bartberger, M. D.; Chen, J.; Chmait, S.; Cupples, R.; Galbreath, E.; Helmering, J.; Hong, F.-T.; Jordan, S.R.; Liu, L.; Kunz, R. K.; Michelsen, K.; Nishimura, N.; Pennington, L. D.; Poon, S. F.; Reid, D.; Sivits, G.; Stec, M. M.; Tadesse, S.; Tamayo, N.; Van, G.; Yang, K.; Zhang, J.; Norman, M. H.; Fotsch, C.; Lloyd, D. J.; Hale, C. "Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogs with Improved Pharmacokinetic Profiles." *Journal of Medicinal Chemistry*, **2014**, 57(2), 325-338.

68. Daniel B. Horne, Nuria A. Tamayo Michael D. Bartberger, Yunxin Bo, Carl D. Davis, Vijay K. Gore, Matthew R. Kaller, Sonya G. Lehto, Vu V. Ma, Nobuko Nishimura, Thomas T. Nguyen, Phi Tang, Weiya Wang, Beth D. Youngblood, Maosheng Zhang, Narendra R. Gavva, Holger Monenschein, and Mark H. Norman "Optimization of Potency and Pharmacokinetic Properties of Tetrahydroisoquinoline Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists" *Journal of Medicinal Chemistry*, **2014**, 57(7), 2989-3004.

69. Nobuko Nishimura, Mark H. Norman, Longbin Liu, Kevin C. Yang, Kate S. Ashton, Michael D. Bartberger, Samer Chmait, Aaron Siegmund, Jie Chen, Rod Cupples, Christopher Fotsch, Roxanne K. Kunz., Steve F. Poon, Glenn Sivits, Joan Helmering, David J. Lloyd, Clarence Hale, and David J. St. Jean, Jr. "Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Interaction: 3. Structure-Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N'-aryl-piperazine Series" *Journal of Medicinal Chemistry*, **2014**, 57(7), 3094-3116.

70. Fang-Tsao Hong, Mark H. Norman, Kate S. Ashton, Michael D. Bartberger, Jie Chen, Samer Chmait, Rod Cupples, Samer Chmait, Christopher Fotsch, Steven R. Jordan, David J. Lloyd, Seifu Tadesse, Clarence Hale, and David J. St. Jean, Jr. "Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Interaction: 4. Exploration of a Novel Binding Pocket" *Journal of Medicinal Chemistry*, **2014**, 57(14), 5949-5964.

71. Kate S. Ashton, Mitchell Denti, Mark H. Norman, and David J. St. Jean, Jr. "A general method for the facile synthesis of optically active 2-substituted piperazines via functionalized 2,5-diketopiperazines" *Tetrahedron Letters*, **2014**, 55(32), 4501-4504.
72. Raju Subramanian, Divesh Aidasani, Keith Bailey, Dan Branstetter, Nancy Everds, Jian Jiang, Mark H. Norman, Ronya Primack, Irene Soto, Markian M. Stec, Mylo Wagner, Tian Wu, Xiaochun Zhu, and Hervé Lebrech "P450 Mediated O-Demethylated Metabolite is Responsible for Rat Hepatobiliary Toxicity of Pyridyltriazine-Containing Kinase Inhibitors" *Toxicological Sciences*, **2014**, 142(1), 298-310.
73. Brian A. Lanman, Anthony B. Reed, Victor J. Cee, Fang-Tsao Hong, Liping H. Pettus, Ryan P. Wurz, Kristin L. Andrews, Jian Jiang, John D. McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Ling Wang, Douglas A. Whittington, Tian Wu, Leeanne Zalameda, Nancy Zhang, Andrew S. Tasker, Paul E. Hughes, and Mark H. Norman "Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511" *Bioorganic & Medicinal Chemistry Letters* **2014**, 5630-5634.
74. Adrian L. Smith, Kristin L. Andrews, Holger Beckmann, Steven F. Bellon, Pedro J. Beltran, Shon Booker, Young-Ah Chung, Noel D. D'Angelo, Kenneth R. Dellamaggiore, Peter Jaeckel, Katja Labitzke, Silvia Materna-Reichelt, Petia Mitchell, Mark H. Norman, David Powers, Mark Rose, Paul Shaffer, Michelle M. Wu, and J. Russell Lipford "Discovery of 1H-Pyrazol-3(2H)-ones as Potent and Selective Inhibitors of Protein Kinase R-like Endoplasmic Reticulum Kinase (PERK)" *Journal of Medicinal Chemistry*, **2015**, 58(3), 1426-1441.
75. Nuria A. Tamayo, Mark H. Norman, Michael D. Bartberger, Fang-Tsao Hong, Yunxin Bo, Longbin Liu, Nobuko Nishimura,[†] Kevin C. Yang, Seifu Tadesse, Christopher Fotsch, Jie Chen, Samer Chmait, Rod Cupples, Clarence Hale, Steven R. Jordan, David J. Lloyd, Glenn Sivits, Gwyneth Van, and David J. St. Jean, Jr. "Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis" *Journal of Medicinal Chemistry*, **2015**, 58, 4462-4482.
76. Markian M. Stec, Kristin L. Andrews, Yunxin Bo, Sean Caenepeel, John McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Nuria Tamayo, Douglas A. Whittington, Tian Wu, Leeanne P. Zalameda, Paul E. Hughes, and Mark H. Norman "The imidazopyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors" *Bioorganic & Medicinal Chemistry Letters*, **2015**, 4136-4142.
77. Lewis D. Pennington, Michael D. Bartberger, Michael D. Croghan, Kristin L. Andrews, Kate S. Ashton, Matthew P. Bourbeau, Jie Chen, Samer Chmait, Rod Cupples, Christopher Fotsch,[†] Joan Helmering, Fang-Tsao Hong, Randall W. Hungate, Steven R. Jordan, Ke Kong, Longbin Liu, Klaus Michelsen, Carolyn Moyer, Nobuko Nishimura, Mark H. Norman, Andreas Reichelt,[†] Aaron C. Siegmund, Glenn Sivits, Seifu Tadesse, Christopher M. Tegley, Gwyneth Van, Kevin C. Yang, Guomin Yao, Jiandong Zhang, David J. Lloyd, Clarence Hale, and David J. St. Jean, Jr. "Discovery and Structure-Guided

Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase–Glucokinase Regulatory Protein (GK–GKRP) Binding: Strategic Use of a N→S ($n_N \rightarrow \sigma^*_{S-X}$) Interaction for Conformational Constraint” *Journal of Medicinal Chemistry*, **2015**, 58, 9663–9679.


78. Dellamaggiore, Kenneth; Mitchell, Petia; Smith, Adrian; Babij, Carol; Wu, Michelle Min; Chung, Young-Ah; Fernando, Manory; Rose, Mark; Norman, Mark H.; Hollenback, David; Burgess, Teresa; Kendall, Richard; Beltran, Pedro; Lipford, J. Russell “Paradoxical Activation of PERK by Kinase Inhibitors can be Exploited to Selectively Impair Tumor Cell Viability” *Cancer Discovery*, submitted, **2016**.

79. Longbin Liu, Josette Carnahan, Howie Bregman, Zihao Hua, Matthew Martin, Matthew Lee, Kevin Yang, Shuyan Yi, Douglas A. Whittington, Linda F. Epstein, Nobuko Nishimura, Richard Lewis, Joseph L. Kim, Michele Potashman, Karina Vaida, Carol Babij, Manory Fernando, and Mark H. Norman “Purinyipyridinylamino-Based DFG-in/ α C-helix-out B-Raf inhibitors: Applying Mutant versus Wild-type B-Raf Selectivity Indices for Compound Profiling” *Bioorganic & Medicinal Chemistry*, **2016**, 24(10), 2215-2234.

80. Liping H. Pettus, Kristin L. Andrews, Shon K. Booker, Jie Chen, Victor J. Cee, Frank Chavez Jr., Yuping Chen, Heather Eastwood, Nadia Guerrero, Bradley Herberich, Dean Hickman, Brian A. Lanman, Jimmy Laszlo III, Matthew R. Lee, J. Russell Lipford, Bethany Mattson, Christopher Mohr, Yen Nguyen, Mark H. Norman, David Powers, Anthony B. Reed, Karen Rex, Christine Sastri, Nuria Tamayo, Paul Wang, Jeffrey T. Winston, Bin Wu, Tian Wu, Ryan P. Wurz, Yang Xu, Yihong Zhou, Andrew S. Tasker, and Hui-Ling Wang “Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors” *Journal of Medicinal Chemistry*, **2016**, 59, 6407-6430.

81. Hui-Ling Wang, Kristin Andrews, Shon K. Booker, Jude Canon, Victor J. Cee, Frank Chavez Jr., Yuping Chen, Heather Eastwood, Nadia Guerrero, Bradley Herberich, Dean Hickman, Brian A. Lanman, Jimmy Laszlo III, Matthew R. Lee, J. Russell Lipford, Bethany Mattson, Christopher Mohr, Yen Nguyen, Mark H. Norman, Liping H. Pettus, David Powers, Anthony B. Reed, Karen Rex, Christine Sastri, Nuria A. Tamayo, Paul Wang, Jeffrey T. Winston, Bin Wu, Qiong Wu, Tian Wu, Ryan P. Wurz, Yang Xu, Yihong Zhou, and Andrew S. Tasker “Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino) quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies” *Journal of Medicinal Chemistry*, **2019**, 62, 1523-1540.

PRESENTATIONS



1. Clayton H. Heathcock, Mark H. Norman, and Daniel A. Dickman, "An Approach to the Total Synthesis of (3H)-Indoline Alkaloids" Presented at the Princess Congress I, Bangkok, Thailand, December 12, **1987**.
2. Mark H. Norman, "The Development of BW1192U90 as an Atypical Antipsychotic Agent" Presented at the Burroughs Wellcome Co. Division Directors Meeting, Research Triangle Park, NC, May 8, **1992**.
3. Mark H. Norman, "Development of BW1192U90 as an Atypical Antipsychotic Agent" Presented at the 5th Biennial Wellcome Chemistry Symposium, Beckenham, United Kingdom, May 5, **1993**.
4. Mark H. Norman, Greg C. Rigdon, Frank Navas III, and Barrett R. Cooper, "Synthesis and Biological Evaluation of a Series of Cyclic Benzamides as Potential Atypical Antipsychotic Agents" Presented at the Gordon Research Conference in Medicinal Chemistry, New London, NH, August 7-12, **1994**.
5. Mark H. Norman, Greg C. Rigdon, Frank Navas III, and Barrett R. Cooper, "Cyclic Benzamides as Potential Atypical Antipsychotic Agents: Synthesis and Biological Activity" Presented at the 208th National Meeting of the American Chemical Society, Washington DC, August 21-26, **1994**.
6. Greg C. Rigdon and Mark H. Norman, "Behavioral Pharmacology of BW1205U90, A Saturated Phthalazinone with Mixed Dopamine and Serotonin Antagonistic Activity" Presented at the Society for Neuroscience Meeting, Miami FL, November 14-18, **1994**.
7. Mark H. Norman, Douglas J. Minick, and Greg C. Rigdon, "Potential Antipsychotic Activity of a Series of Phthalimide and Isoindolinone Derivatives: Conformational and Biological Effects of Bridging Unit Alterations" Presented at IBC's First International Symposium on Schizophrenia: Latest Advances in Understanding and Drug Development, Philadelphia, PA, May 8-9, **1995**.

8. Mark H. Norman, Frank Navas III, and Greg C. Rigdon, "Synthesis and Preliminary Pharmacology of a Mixed D₂ / 5-HT₂ Antagonist, BW1205U90" Presented at IBC's First International Symposium on Schizophrenia: Latest Advances in Understanding and Drug Development, Philadelphia, PA, May 8-9, **1995**.
9. Michael J. Durcan, Greg C. Rigdon, Mark H. Norman, and Philip F. Morgan, "The Apparent Relative Selectivity of Dopamine Antagonists for Dopamine D₂ and D₄ Receptor Clones Depends on the Radioligand Used" Presented at the Society for Neuroscience Meeting, San Diego, CA, November 11-16, **1995**.
10. Mark H. Norman, Michael J. Bishop, Stephen J. Hodson, Frank Navas III, and Eric C. Bigham, "Design and Monomer Selection of an 18,432 Member Library Targeting 7-TM Receptors" Presented at the first Glaxo Wellcome International Chemistry Symposium, Stevenage, UK, April 23-26, **1996**.
11. Mark H. Norman, Frank Navas III, and Greg C. Rigdon, "SAR Investigations of a Series of Benzamides: The Discovery of a Potential Atypical Antipsychotic Agent" Presented at the 212th National Meeting of the American Chemical Society, Orlando, FL, August 25-29, **1996**.
12. Michele Carmouche, Anthony W. Bannon, Jennifer Seda, J. M. Francis, Mark H. Norman, William Karbon and Michael L. McCaleb "Behavioral Characterization of Neuropeptide Y Knockout Mice" Presented at the Society for Neuroscience Meeting, San Diego, CA, November 4-9, **2000**.
13. Mark H. Norman, Ning Chen, Zhidong Chen, Chris Fotsch, Ray Hurt, Clarence Hale, Bruce Han, Tracy Jenkins, John Kincaid, Longbin Liu, Yuelie Lu, Ofir Moreno, Vincent Santora, Jennifer D. Sonnenberg, and William Karbon, "Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine derivatives as NPY-5 Receptor Antagonists" Presented at the 6th International NPY Conference, Sydney Australia, April 22-26, **2001**.
14. Mark H. Norman, Ning Chen, Zhidong Chen, Chris Fotsch, Clarence Hale, Bruce Han, Tracy Jenkins, John Kincaid, Longbin Liu, Yuelie Lu, Vincent Santora, Jennifer D. Sonnenberg, and William Karbon, "Synthetic Approaches Directed Toward the Preparation of Pyrrolo[3,2-d]pyrimidine Derivatives: Potent Small Molecule NPY-5 Receptor Antagonists" Presented at the 6th International NPY Conference, Sydney Australia, April 22-26, **2001**.
15. John Kincaid, Ning Chen, Zhidong Chen, Chris Fotsch, Ray Hurt, Clarence Hale, Bruce Han, Tracy Jenkins, Longbin Liu, Yuelie Lu, Ofir Moreno, Vincent Santora, Jennifer D. Sonnenberg, William Karbon, and Mark H. Norman, "Pyrrolo[3,2-d]pyrimidine Derivatives as Potent Small Molecule NPY-5 Receptor Antagonists – Part I: Synthetic Strategies" Presented at the 222nd National American Chemical Society Meeting, Chicago, IL, August 26-30, **2001**.
16. John Kincaid, Ning Chen, Zhidong Chen, Chris Fotsch, Clarence Hale, Bruce Han, Tracy Jenkins, Longbin Liu, Yuelie Lu, Vincent Santora, Jennifer D. Sonnenberg, William Karbon, and Mark H. Norman, "Pyrrolo[3,2-d]pyrimidine Derivatives as Potent Small Molecule NPY-5 Receptor Antagonists – Part II: Structure Activity Relationships" Presented at the 222nd National American Chemical Society Meeting, Chicago, IL, August 26-30, **2001**.

17. Ning Chen, Christopher Fotsch, Jennifer D. Sonnenberg, Ning Chen, Clarence Hale, William Karbon, and Mark H. Norman "Synthesis and Structure-Activity Relationships of a Trisubstituted Phenyl Urea Derivatives as Neuropeptide Y5 receptor Antagonists" Presented at the 222nd National American Chemical Society Meeting, Chicago, IL, August 26-30, **2001**.
18. Premilla Arasasingham, Chris Fotsch, Xiaohu Ouyang, Mark H. Norman, Michael G. Kelly, Kevin L. Stark, William Karbon, Clarence Hale, Jamie Baumgartner, Martha Zambrano, and Nuria A Tamayo "SAR of (1-Aryl-2-piperizinylethyl)piperazines and substituted Indoles: Antagonists for the AGRP/Melanocortin Receptor Binding" Presented at the 222nd National American Chemical Society Meeting, Chicago, IL, August 26-30, **2001**.
19. Robert D. Groneberg, Xicheng Sun, Eli Wallace, Mareli Rodriguez, Andras Toro, David Clarke, David Mareska, Hideo Suzuki, Barb Brandhuber, Guy Vigers, James Rizzi, Jeff Yingling, Kevin Ash, Kevin Koch, and Mark H. Norman, "The Design and Discovery of Mono-Charged inhibitors of PTP1B" Presented at the 5th Winter Conference on Medicinal and Bioorganic Chemistry" Steamboat Springs, Colorado January 26-31, **2003**.
20. Gal Hever, Mark H. Norman, Juia Wang, Rong Kuang, Michael Zhang, Shoushu Jiao, Jean-Claude Louis, Ella Magal, "CDK5 Inhibition as a Target for Neuroprotection in the Rat Model of Middle Cerebral Artery Occlusion" Presented at the Society for Neuroscience 33rd Annual Meeting, New Orleans LA, November 10-14, **2003**.
21. Charles M. Henley; Wieya Wang; Gary Zajic; Narender Gavva; Gal Hever; Juia Wang; Rong Kuang; Shoushu Jiao; Mark H. Norman; Wieya Zhong; Thomas Nguyen; Matt Kaller; Hui-Ling Wang; Robert Rzasa; Jean-Claude Louis, and Ella Magal, "Inhibition of Cdk5 - induced apoptosis correlates with inhibition of retinoblastoma protein phosphorylation" Presented at the Society for Neuroscience 33rd Annual Meeting, New Orleans LA, November 10-14, **2003**.
22. James J. S. Treanor, Rami Tamir, Narender Gavva, Dawn Zhu, Yusheng Qu, T.J. Zhang, Tony Bannon, Frank Porreca, Ken Wild, Ella Magal, Elisabeth M. Doherty, Mark H. Norman, and Jean-Claude Louis, "Competitive TRPV1 Antagonist(s) with Analgesic Properties" Presented at the Society for Neuroscience 33rd Annual Meeting, New Orleans LA, November 10-14, **2003**.
23. Mark H. Norman, Hui-Ling Wang, Robert Rzasa, Wenge Zhong, Tom Nguyen, Matthew Kaller, Hu Liu, Tim Osslund, J.D. Zhang, David Powers, Ling Xiong, Weiya Wang, and Ella Magal, "The Design and Synthesis of Conformationally Constrained Urea Derivatives as Potential CDK-5 Inhibitors" Presented at the Advances in Synthetic, Combinatorial, and Medicinal Chemistry (ASCMC) conference in Moscow Russia, May 16-19, **2004**.
24. Elizabeth M. Doherty, Mark H. Norman, Christopher Fotsch, Yunxin Bo, Partha P. Chakrabarti, Ning Chen, Nianhe Han, Michael G. Kelly, John Kincaid, Lana Klionsky, Qingyian Liu, Vassil I. Ognyanov, Rami Tamir, Queenie Wang, Jiawang Zhu, Narender Gavva, and James J. S. Treanor. "Discovery of Potent, Orally Available Antagonists of the TRPV1 Channel. Structure-Activity Relationship of N-Aryl Cinnamides" Presented at the Medicinal Chemistry International Symposium on Medicinal Chemistry (ISMC), Copenhagen Denmark, August 16-18, **2004**.

25. David A. Mareska, Robert D. Groneberg, Xicheng Sun, Eli Wallace, Mareli Rodriguez, Andras Toro, David Clarke, Hideo Suzuki, Kevin Ash, Jeff Yingling, Guy Vigers, Barb Brandhuber, Jim Rizzi, Laurence E. Burgess, Kevin Koch, Mark H. Norman, Rick Lindberg, John McCarter, and Michael G. Kelly, "Design and evaluation of mono-charged inhibitors of PTP1B" Presented at the 228th ACS National Meeting, Philadelphia, PA, August 22-26, **2004**.
26. Ning Xi, Jeffrey A. Adams, Yunxin Bo, Ning Chen, Michael Croghan, Elizabeth M. Doherty, Nianhe Han, Hongyu Liao, Qingyian Liu, Michael G. Kelly, Mark H. Norman, Markian Stec, Nuria A. Tamayo, Shimin Xu, Janet Cheetham, Duncan M. Smith, Faye Hsieh, Tony Bannon, Clarence Hale, James W. Baumgartner, and Christopher Fotsch, "Design and synthesis of potent, selective melanocortin subtype-4 receptor agonists for the treatment of obesity" Presented at the 228th ACS National Meeting, Philadelphia, PA, August 22-26, **2004**.
27. Xianghong Wang; Elizabeth M. Doherty, Mark H. Norman, Christopher Fotsch, Michael G. Kelly, Yunxin Bo, Partha Chakrabarti, Ning Chen, Bruce Han, John Kincaid; Qingyian Liu, Vassil I. Ognyanov; Joe Zhu, Rami Tamir; Steve Edenson, Narendra Gavva, Jean-Claude Louis, James J. S. Treanor, "Discovery of Potent Antagonists of the TRPV1 Channel. Structure-Activity Relationship of N-Aryl Cinnamides" Presented at the Society for Neuroscience 34th Annual Meeting, San Diego CA, October 23-27, **2004**.
28. Anthony W. Bannon, James R. Davis, Dawn Zhu, Mark H. Norman, Elizabeth M. Doherty, Ella Magal, James J. S. Treanor. "Involvement of TRPV1 in the regulation of Body Temperature in Rats and Mice" Program No. 890.24. Presented at the Society for Neuroscience 34th Annual Meeting, San Diego CA, October 23-27, **2004**.
29. Gal Hever, Rong Kuang, Jue Wang, Shoushu Jiao, Sekhar Surapaneni, A. Bak, Mark H. Norman, James S. Treanor, Jean-Claude Louis, and Ella Magal "A Novel VR1 Antagonist Inhibits Thermal Hyperalgesia Evoked by Carrageenan Injection in the Rat Paw" Program No. 864.1. Presented at the Society for Neuroscience 34th Annual Meeting, San Diego CA, October 23-27, **2004**.
30. Jue Wang, Rong Kuang, Gal Hever, Shoushu Jiao, Sekhar Surapaneni, Annette Bak, Mark H. Norman, James S. Treanor, Jean-Claude Louis, and Ella Magal. "Therapeutic Effect of an Orally Administered VR1 Antagonist in a Rat Model of Complete Freund's Adjuvant (CFA) Induced Thermal Hyperalgesia" Program No. 864.6. Presented at the Society for Neuroscience 34th Annual Meeting, San Diego CA, October 23-27, **2004**.
31. Mark H. Norman, Vassil I. Ognyanov, Vijay Gore, Chenera Balan, Yunxin Bo, Ning Xi, Celia Dominguez, Christopher Fotsch, Queenie Wang, Ning Xi, Shimin, Vu V. Ma, Yi-Xin Qian, Rami Tamir, Lana Klionsky, Rongzhen Kuang, Shoushu Jiao, Hong Deng, Jue Wang, Gal Hever, Anthony W. Bannon, Narendra R. Gavva, Jean-Claude Louis, and James J. S. Treanor, "Discovery of 2-(Piperazin-1-yl)-1H-benzimidazoles as Potent, Orally Available Antagonists of the TRPV1 Channel" Presented at the International Society for the Study of Pain meeting in Sydney, Australia, August 21-26, **2005**.
32. Wenge Zhong, Hu Liu, Matthew R. Kaller, Thomas T. Nguyen, Robert M. Rzasa, Hui-Ling Wang, Mark H. Norman, Xiaoling Xiong, David Powers, Weiya Wang, Charles Henley, Ella Magal, Jiandong Zhang, and Timothy Osslund "Quinolin-2(1H)-one derivatives as CDK5 inhibitors" Presented at the 229th American Chemical Society meeting, San Diego, CA, March 13-17, **2005**.

33. Matthew R. Kaller, Wenge Zhong, Thomas T. Nguyen, Robert M. Rzasa, Hui-Ling Wang, Mark H. Norman, Xiaoling Xiong, David Powers, Weiya Wang, Charles Henley, Ella Magal, Jiandong Zhang, and Timothy Osslund, "Design and synthesis of pyridones as CDK5 inhibitors" Presented at the 229th American Chemical Society meeting, San Diego, CA, March 13-17, **2005**.
34. Hui-Ling Wang, Xiaoling Xiong, David Powers, Ella Magal, and Mark H. Norman, "Design and synthesis of benzodiazepinone derivatives as CDK5 inhibitors" Presented at the 229th American Chemical Society meeting, San Diego, CA, March 13-17, **2005**.
35. Robert M. Rzasa, Matthew R. Kaller, Ella Magal, Gang Liu, Thomas T. Nguyen, Timothy Osslund, David Powers, Hui-Ling Wang, Xiaoling Xiong, Jiandong Zhang, Wenge Zhong, and Mark H. Norman, "Design and synthesis of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors" Presented at the 229th American Chemical Society meeting, San Diego, CA, March 13-17, **2005**.
36. Jiawang Zhu, Vellarkad Viswanadhan, Vassil I. Ognyanov, Yunxin Bo, Ning Chen, Partha P. Chakrabarti, Elizabeth M. Doherty, Christopher Fotsch, Narender Gavva, Nianhe Han, Qingyian Liu; Rami Tamir; Xianghong Wang; Yaxiong Sun, James J. S. Treanor, and Mark H. Norman, "Conformational Analyses of N-Aryl Cinnamides as TRPV1 Antagonists" Presented at the 229th American Chemical Society meeting, San Diego, CA, March 13-17, **2005**.
37. Elizabeth M. Doherty, Jiawang Zhu, Ning Chen, Christopher Fotsch, Narender Gavva, Tom Nixey, Nobuko Nishimura, Vassil Ognyanov, Markian Stec, Rami Tamir, James J. S. Treanor, and Mark H. Norman, "Discovery of potent TRPV1 antagonists: Synthesis of amino-substituted heterocycles as isosteres of trans-cinnamides" Presented at the ACS Perspectives in Medicinal Chemistry conference in Boston, MA, June, **2005**.
38. Narender R. Gavva, Rami Tamir, Lana Klionsky, Mark H. Norman, Jean-Claude Louis, Kenneth D. Wild, James J. S. Treanor, "Vanilloid receptor 1 (TRPV1) antagonists with differential pharmacology act through the same binding pocket" Presented at the International Society for the Study of Pain meeting in Sydney, Australia, August 21-26, **2005**.
39. Ella Magal, Anthony W. Bannon, Shoushu Jiao, Sekhar Surapaneni, Annette Bak, Mark H. Norman, Narender Gavva, Jean-Claude Louis, James J. S. Treanor, "Efficacy of a Novel TRPV1 Antagonist, AMG8163, in Various Rat Models of Pain" Presented at the International Society for the Study of Pain meeting in Sydney, Australia, August 21-26, **2005**.
40. Anthony W. Bannon, Rami Tamir, Queenie Wang, Dawn Zhu, April Le, Bradley Youngblood, Rong Kuang, Hong Deng, Jue Wang, Sekhar Surapaneni, Ella Magal, Mark H. Norman, Jean-Claude Louis, James J. S. Treanor, and Narender R. Gavva, "Identification and biological evaluation of AMG0347, ((E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide), a potent vanilloid receptor 1 (TRPV1) antagonist" Presented at the Society for Neuroscience in San Diego, CA, November, **2005**.

41. Queenie Wang, Chenera Balan, Anthony Bannon, Yunxin Bo, Celia Dominguez, Christopher Fotsch, Narendra Gavva, Vijay Gore, Lana Klionsky, Vu Ma, Vassil I. Ognyanov, Yi-Xin Qian, Rami Tamir, James J. S. Treanor, Ning Xi, Shimin Xu, Dawn Zhu, and Mark H. Norman, “Structure-Activity Relationship of 2-(4-(Pyridin-2-yl)piperazin-1-yl)-1H-benzo[d]imidazoles as Potent, Orally Available TRPV1 Antagonists” Presented at the Pacific Chemistry conference in Honolulu, HI, December 17-22, **2005**.
42. Ma, Vu V.; Gore, Vijay K.; Xi, Ning; Ognyanov, Vassil I.; Tamir, Rami; Treanor, James J. S.; Gavva, Narendra R.; Norman, Mark H.. “Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists” Presented at the 231st American Chemical Society meeting, Atlanta, GA, March 26-30, **2006**.
43. Gore, Vijay K.; Balan, Chenera; Bannon, Anthony W.; Bo, Yunxin; Dominguez, Celia; Fotsch, Christopher; Ognyanov, Vassil I.; Klionsky, Lana; Ma, Vu V.; Qian, Yi-Xin; Tamir, Rami; Wang, Xianghong; Xi, Ning; Xu, Shimin; Zhu, Dawn; Gavva, Narendra R.; Treanor, James J. S.; Norman, Mark H. “2-(Piperazin-1-yl)-1H-benzimidazoles as potent, orally available antagonists of the TRPV1 channel” Presented at the 232nd American Chemical Society meeting, San Francisco, CA, Sept. 10-14, **2006**.
44. Norman, Mark H.; Fotsch, C.; Doherty, E. M.; Bo, Y.; Chen, N.; Chakrabarti, P.; Gavva, N. R.; Nishimura, N.; Nixey, T.; Ognyanov, V. I.; Rzasa, R.; Stec, M.; Surapaneni, S.; Tamir, R.; Viswanadhan, V.; Zhu, J.; Treanor, J. J. S. “Conformationally Restricted Analogues of *trans*-Cinnamides: Discovery of Substituted Pyrimidines as Potent TRPV1 Antagonists” Presented at the XIXth International Symposium on Medicinal Chemistry in Istanbul Turkey, August 29-September 2, **2006**.
45. Tamir, R.; Bannon, A. W.; Klionsky, L.; Le, A.; Youngblood, B.; Zhu, D.; Surapaneni, S.; Hovland, D. Lehto, S. G.; Louis, J-C.; Magal, E. Norman, M. H.; Treanor, J. J. S.; and Gavva, N. R. “Peripherally-restricted TRPV1 antagonists induce transient hyperthermia” Presented at the Society for Neuroscience 36th Annual Meeting in Atlanta, GA, **2006**.
46. Gavva, N. R.; Bannon, A.W.; Immke, D.C.; Tamir, R.; Klionsky, L.; Hever, Wang, J.; Kuang, R.; Wang, W. Davis, J.; Zajic, G. Arik, L.; Shi, L.; Bak, A.; Surapaneni, S.; Hovland, D.; Louis, J-C.; Norman, M. H.; Magal, E. Treanor, J. J. S. “Preclinical pharmacology of AMG 517: A novel TRPV1 antagonist in the clinic” Presented at the Society for Neuroscience 36th Annual Meeting in Atlanta, GA **2006**.
47. Mark H. Norman, “TRPV1 Antagonists: A Case Study- from High Throughput Screening to Human Clinical Trials” Presented at the Cambridge Healthtech Institute’s ‘Mastering Medicinal Chemistry’ Conference in San Francisco, CA, February, **2007** (Invited Speaker).
48. Mark H. Norman, “Small Molecule Drug Discovery TRPV1 Antagonists: A Case Study” Presented at the Cambridge Healthtech Institute’s ‘Mastering Medicinal Chemistry’ Presented at California Lutheran University, April 15, **2007** (Invited Speaker).

49. Sonya G. Lehto, Rami Tamir, Dawn Zhu, April Le, Brad Youngblood, Ella Magal, James J. S. Treanor, Mark H. Norman, Jean-Claude Louis, and Narender R. Gavva “Differential pharmacology of TRPV1 antagonists determines the magnitude of body temperature changes in rats” Presented at the 2nd International Conference on Neuropathic Pain, Berlin, Germany, June 7-10, **2007**.
50. Xianghong Wang, Partha P. Chakrabarti, Vassil I. Ognyanov, Liping H. Pettus, Rami Tamir, Helming Tan, Phi Tang, James J. S. Treanor, Narender R. Gavva, and Mark H. Norman “Design of Trisubstituted Pyrimidines as Vanilloid Receptor 1 (TRPV1) Antagonists with Improved Solubility” Presented at the 234th American Chemical Society Meeting, Boston, MA, August 19-23, **2007**.
51. Vellarkad Viswanadhan, Yaxiong Sun, and Mark H. Norman “3D-QSARs and activity predictions of human TRPV1 channel antagonists: CoMFA and CoMSIA analyses” Presented at the 234th American Chemical Society Meeting, Boston, MA, August 19-23, **2007**.
52. Andrej A. Romanovsky, Alexandre A. Steiner, Victoria F. Turek, Maria C. Almeida, Jeffrey J. Burmeister, Daniela L. Oliveira, Jennifer L. Roberts, Anthony W. Bannon, Mark H. Norman, Jean-Claude Louis, James J. S. Treanor, Narender R. Gavva “Non-thermal activation of TRPV1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors” Presented at the Transient Receptor Potential Ion Channel Superfamily Keystone Symposium Symposia, September 18-23, **2007**, Breckenridge, CO.
53. Doherty, Elizabeth M.; Fotsch, Christopher; Bannon, Anthony W.; Bo, Yunxin; Chen, Ning; Dominguez, Celia; Falsey, James; Gavva, Narender R.; Katon, Jodie; Nixey, Thomas; Ognyanov, Vassil I.; Pettus, Liping; Rzasa, Robert M.; Stec, Markian; Surapaneni, Sekhar; Tamir, Rami; Zhu, Jiawang; Treanor, James J. S.; Norman, Mark H.. “TRPV1 antagonists: SAR and the Selection of AMG 517 as a Clinical Candidate” Presented at the Western Regional Meeting ACS, October 11, **2007**, San Diego CA.
54. Andrej A. Romanovsky, Alexandre A. Steiner, Victoria F. Turek, Maria C. Almeida, Jeffrey J. Burmeister, Daniela L. Oliveira, Jennifer L. Roberts, Anthony W. Bannon, Mark H. Norman, Jean-Claude Louis, James J. S. Treanor, Narender R. Gavva “Non-thermal activation of TRPV1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors” Presented at the Society for Neuroscience 37th Annual Meeting, November 5-8, **2007**, San Diego, CA.
55. Narender R. Gavva, Andras Garami, Liang Fang, Sekhar Surapaneni, Anna Akrami, Francisco Alvarez, Annette Bak, Mary Darling, Anu Gore, Graham R. Jang, Patrick Kesslak, Liyun Ni, Mark H. Norman, Gabrielle Palluconi, Mark J. Rose, Margaret Salfi, Edward Tan, James J. S. Treanor, Andrej Romanovsky, Christopher Banfield, and Gudarz Davar “The Capsaicin Receptor TRPV1: Is it a Pain Transducer or a Regulator of Body Temperature?” Presented at the Society for Neuroscience 37th Annual Meeting, November 5-8, **2007**, San Diego, CA.
56. Mark H. Norman, “Small Molecule Drug Discovery TRPV1 Antagonists: A Case Study” Presented at California State Northridge, March 5, **2008**, Northridge CA (Invited Speaker).
57. Aaron Siegmund, Steve Bellon, Shon Booker, Alan Cheng, Derin D’Amico, Noel D’Angelo, Tae-Song Kim, Jasmine Lin, Mark Stec, Ning Xi, Kevin Yang, Yajing Yang, Yihong Zhang, Mark H. Norman, Isabelle Dussault, Jean-Christophe Harmange, and Longbin Liu “Pyridazinones as Potent and Selective cMET Kinase Inhibitors” Presented at the Keystone Computer-Aided Drug Design Symposia, March 29 - April 3, 2008, **2008**, Steamboat Springs, CO.

58. Steve Bellon, David Bauer, Shon Booker, Debbie Choquette, Isabelle Dussault, Yan Gu, Jean-Christophe Harmange, Tae-Seong Kim, Matt Lee, Longbin Liu, Alex Long, Mark H. Norman, Anne O'Connor, Paul Rose, Aaron Siegmund, Doug Whittington, Ning Xi, and Michael Zhang "Designing selective c-Met inhibitors: A structural approach" Presented at the AACR meeting, April 14-18, **2008**, San Diego, CA.
59. Deborah Choquette, Longbin Liu, Tae-Seong Kim, Mark H. Norman, Aaron Siegmund, Ning Xi, Steven F. Bellon, Paula Kaplan-Lefko, Matthew Lee, Jasmine Lin, Karen Rex, Yohannes Teffera, Isabelle Dussault, Jean-Christophe Harmange "Discovery of 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458): A Potent, Selective, and Orally Bioavailable c-Met Inhibitor" Presented at the AACR meeting, April 14-18, **2008**, San Diego, CA.
60. Narender R. Gavva, Andras Garami, Liang Fang, Sekhar Surapaneni, Anna Akrami, Francisco Alvarez, Annette Bak, Mary Darling, Anu Gore, Graham R. Jang, Patrick Kesslak, Liyun Ni, Mark H. Norman, Gabrielle Palluconi, Mark J. Rose, Margaret Salfi, Edward Tan, James J. S. Treanor, Andrej Romanovsky, Christopher Banfield, and Gudarz Davar "AMG 517, a selective TRPV1 antagonist causes marked hyperthermia in humans" Presented at the Spring Pain Conference, Grand Cayman, British West Indies, April 26-May 2, **2008**.
61. Nuria Tamayo, Hongyu Liao, Markian M. Stec, Xianghong Wang, Partha Chakrabarti, Dan Retz, Elizabeth M. Doherty, Sekhar Surapaneni, Rami Tamir, Anthony W. Bannon, Narender R. Gavva, and Mark H. Norman "Can we identify Transient Receptor Potential Vanilloid 1 (TRPV1) antagonists that do not cause hyperthermia?" Presented at the Cambridge Healthtech Institute "Targeting Pain with Novel Therapeutics", May 12-13, **2008**, Philadelphia, PA (Invited Speaker).
62. Mark H. Norman, "TRPV1 Antagonists: From High Throughput Screening to the Selection of a Clinical Candidate and Beyond" Presented at the 17th International Conference on Organic Synthesis, June 22-27, **2008**, Daejeon, Korea (Invited Speaker).
63. Vu V. Ma, Vijay K. Gore, Ruoyuan Yin, Joe Ligutti, David Immke, Elizabeth M. Doherty, and Mark H. Norman "Structure activity relationship (SAR) investigations of tetrahydroquinolines as BKCa agonists." Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, **2008**.
64. Mark H. Norman, "Discovery of a Selective TRPV1 Antagonist, AMG 517: A Clinical Candidate for the Treatment of Pain" Presented at the XXth International Symposium on Medicinal Chemistry, September 1-6, **2008**, Vienna, Austria (Invited Speaker).
65. Tamayo, Nuria; Liao, Hongyu; Stec, Markian M.; Wang, Xianghong; Chakrabarti, Partha; Retz, Dan; Doherty, Elizabeth M.; Surapaneni, Sekhar; Tamir, Rami; Bannon, Anthony W.; Gavva, Narender R.; Norman, Mark H. "Peripherally Restricted Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists" Presented at the "Ion Channels as Therapeutic Targets" Boston MA, October 21-23, **2008** (Invited Speaker).

66. Wang, Hui-Ling; Katon, Jodie; Balan, Chenera; Bannon, Anthony W.; Bernard, Charles; Doherty, Elizabeth M.; Dominguez, Celia; Gavva, Narender R.; Gore, Vijay; Ma, Vu; Nishimura, Nobuko; Surapaneni, Sekhar; Tang, Phi; Tamir, Rami; Thiel, Oliver; Treanor, James J. S.; Norman, Mark H.. “Design & Synthesis of TRPV1 Antagonists with Improved Physicochemical and Pharmacokinetic Properties” Presented at the Cambridge Healthtech Institute’s ‘Mastering Medicinal Chemistry’ Conference in San Francisco, CA, February 27, **2009** (Invited Speaker).
67. Mark H. Norman, “Small Molecule Drug Discovery TRPV1 Antagonists: A Case Study” Presented at the 50-year awards luncheon of CalPACS (American Chemical Society), October 3, **2009** (Invited Speaker).
68. Kenneth D. Wild, Sonya G. Lehto, Sunny Chen, Jeff Clarine, Carl Davis, Hong Deng, Anu Gore, Lana Klionsky, Holger Monenschein, Mark H. Norman, Karthik Nagapudi, Nuria Tamayo, Judy Wang, Tingrong Wang, Weiya Wang, Brad Youngblood, Maosheng Zhang, Dawn Zhu, James J.S. Treanor, and Narender R. Gavva “TRPM8 selective antagonists are not effective in rat models of pain” Presented at the Spring Pain Conference, Grand Cayman, British West Indies, April 17-April 24, **2010**.
69. Sonya G. Lehto, Sunny Chen, Jeff Clarine, Carl Davis, Hong Deng, Anu Gore, Lana Klionsky, Holger Monenschein, Mark H. Norman, Karthik Nagapudi, Nuria Tamayo, Judy Wang, Tingrong Wang, Weiya Wang, Brad Youngblood, Maosheng Zhang, Dawn Zhu, James J.S. Treanor, Kenneth D. Wild, and Narender R. Gavva “TRPM8 selective antagonists are not effective in rat neuropathic or inflammatory pain models” Presented at the Third International Congress on Neuropathic Pain, Athens, Greece, May 27-30, **2010**.
70. Monenschein, Holger; Bo, Yunxin; Clarine, Jeffrey; Davis, Carl; Deng, Hong; Gore, Vijay; Horne, Daniel; Horner, Michelle; Kaller, Matthew; Lehto, Sonya; Ma, Vu; Nagapudi, Karthik; Nguyen, Thomas; Nishimura, Nobuko; Norman, Mark; Tamayo, Nuria; Treanor, James; Wang, Yueh-Ju; Wang, Tingrong; Wang, Weiya; Wild, Kenneth; Youngblood, Bradley; Zhang, Maosheng; Zhong, Wenge; Zhu, Dawn; Gavva, Narender. “Development of TRPM8 selective antagonists for the treatment of inflammatory and neuropathic pain” Presented at the 240th American Chemical Society Meeting, Boston, MA, August 22-26, **2010**.
71. Mark H. Norman, “Red Hot Chili Peppers - Small Molecule Drug Discovery Recipes for the Treatment of Pain” Presented at the University of New Hampshire, November 8, **2010**, Durham, NH (Invited Speaker).
72. Bradley D. Youngblood, Hong Deng, Dawn Zhu, Weiya Wang, Judy Wang, Tingrong Wang, Maosheng Zhang, Holger Monenschein, Mark H. Norman, Nuria Tamayo, Sunny Chen, Carl Davis, Jeff Clarine, James J.S. Treanor, Kenneth D. Wild, Sonya G. Lehto, and Narender R. Gavva “Transient Receptor Potential Melastatin 8 antagonists do not prevent acute oxaliplatin-induced painful hypersensitivity to cold in rats” Presented at the 2010 Society for Neuroscience (SFN) San Diego, CA Nov 14th, **2010**.

73. Nuria A. Tamayo, Yunxin Bo, Vijay Gore, Vu Ma, Nobuko Nishimura, Phi Tang, Sonia Letho, Narender R. Gavva, and Mark H. Norman "TRPM8 Channel: A Target for the Treatment of Pain" Presented at the World Pharma Congress Drug Discovery Summit on *Targeting Pain with Novel Therapeutics* in Philadelphia, PA, June 7-8, **2011**.
74. Noel D. D'Angelo, Tae-Seong Kim, Kristin Andrews, Shon K. Booker, Sean Caenepeel, Kui Chen, Derin D'Amico, Dan Freeman, Jian Jiang, Longbin Liu, John D. McCarter, Tisha San Miguel, Erin L. Mullady, Michael Schrag, Raju Subramanian, Jin Tang, O Robert C. Wahl, Ling Wang, Douglas A. Whittington, Tian Wu, Ning Xi, Yang Xu, Peter Yakowec, Kevin Yang, Leeanne P. Zalameda, Nancy Zhang, Paul Hughes, and Mark H. Norman "Discovery and Optimization of a Series of Benzothiazole PI3K / mTOR Dual Inhibitors" Presented at the 242nd National American Chemical Society meeting in Denver Colorado, August 28-September 1, **2011**.
75. Markian M. Stec, Kristin L. Andrews, Shon K. Booker, Sean Caenepeel, Daniel J. Freeman, Jian Jiang, Hongyu Liao, John McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Nuria Tamayo, Ling Wang, Kevin Yang, Leeanne P. Zalameda, Nancy Zhang, Paul E. Hughes, and Mark H. Norman "Investigations of Various Heterocycles to Improve Metabolic Stability within a Series of PI3K/mTOR Dual Inhibitors" Presented at the 242nd National American Chemical Society meeting in Denver Colorado August 28-September 1, **2011**.
76. Kevin Yang, Nobuko Nishimura, Aaron Siegmund, Longbin Liu, Marian C. Bryan, Kristin L. Andrews, Yunxin Bo, Shon K. Booker, Sean Caenepeel, Daniel Freeman, Hongyu Liao, John McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Nuria Tamayo, Ling Wang, Douglas A. Whittington, Leeanne Zalameda, Nancy Zhang, Paul E. Hughes, and Mark H. Norman "Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives as Potent PI3K/mTOR Dual Inhibitors" Presented at the American Chemical Society Western Regional Meeting in Pasadena, CA, November 10-11, **2011**.
77. Nancy Zhang, Sean Caenepeel, Ling Wang, Mark H. Norman, Terri Burgess, Richard Kendall, Robert Radinsky, Paul E. Hughes, Daniel J. Freeman "AMG 511, a Potent and Selective Class I PI3K Inhibitor, Demonstrates Anti-Tumor Activity in Multiple Xenograft Models" Presented at the American Association for Cancer Research (AACR) in Chicago, IL, March 31-April 4, **2012**.
78. Sean Caenepeel, Nancy Zhang, Ling Wang, Mark H. Norman, Terri Burgess, Robert Radinsky, Rick Kendall, Daniel Freeman, Paul E. Hughes "In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer" Presented at the American Association for Cancer Research (AACR) in Chicago, IL, March 31-April 4, **2012**.
79. Mark H Norman "Selective Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors: Identification of a Clinical Candidate" Presented at the BIT Life Sciences 3rd Annual International Conference of Medichem in Beijing China, May 10-14, **2012** (Invited Speaker and Chairman).

80. Fang-Tsao Hong, Adrian L. Smith, Noel D. D'Angelo, Yunxin Y. Bo, Shon K. Booker, Victor J. Cee, Brad Herberich, Claire L. M. Jackson, Brian A. Lanman, Longbin Liu, Nobuko Nishimura, Liping H. Pettus, Anthony B. Reed, Seifu Tadesse, Nuria A. Tamayo, Ryan P. Wurz, Kevin Yang, Kristin L. Andrews, Douglas A. Whittington, John D. McCarter, Tisha San Miguel, Leeanne Zalameda, Jian Jiang, Raju Subramanian, Erin L. Mullady, Sean Caenepeel, Daniel J. Freeman, Ling Wang, Nancy Zhang, Tian Wu, Paul E. Hughes, and Mark H. Norman "Identification of a Novel Series of Highly Potent and Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases for the Treatment of Cancer" Presented at the 244th American Chemical Society Meeting, Philadelphia, PA, August 19-23, **2012**.

81. Nuria A. Tamayo, Yunxin Bo, Vijay Gore, Vu Ma, Nobuko Nishimura, Phi Tang, Hong Deng, Lana Klionsky, Sonya G. Lehto, Weiya Wang, Brad Youngblood, Jiyun Chen, Narender R. Gavva, and Mark H. Norman "The Discovery and Structure-Activity Relationships of a Novel Series of Fused Piperidines as Potent TRPM8 Antagonists" Presented at the 244th American Chemical Society Meeting, Philadelphia, PA, August 19-23, **2012**.

82. Wurz, Ryan P.; Andrews, Kristin L.; Bo, Yunxin Y.; Booker, Shon K.; Caenepeel, Sean; Cee, Victor J.; Noel, D'Angelo D.; Freeman, Daniel J.; Herberich, Bradley J.; Hong, Fang-Tsao; Jackson, Claire L.; Jiang, Jian; Lanman, Brian A.; Liu, Longbin; McCarter, John D.; Mullady, Erin L.; Nishimura, Nobuko; Pettus, Liping H.; Reed, Anthony B.; San Miguel, Tisha; Smith, Adrian L.; Stec, Markian M.; Tadesse, Seifu; Tasker, Andrew S.; Aidasani, Divesh; Zhu, Xiaochun; Subramanian, Raju; Tamayo, Nuria A.; Wang, Ling; Whittington, Douglas A.; Wu, Bin; Wu, Tian; Yang, Kevin; Zalameda, Leeanne; Zhang, Nancy; Hughes, Paul E.; Norman, Mark H. "Identification of AMG 511 as a selective class I phosphoinositide 3-kinase inhibitor", Abstracts of Papers, 245th ACS National Meeting & Exposition, New Orleans, LA, United States, April 7-11, **2013**.

83. Mark H. Norman, Kate S. Ashton, Kristin L. Andrews, Marion C. Bryan, Michael D. Bartberger, Jie Chen, Kui Chen, Michelle Chen, Michael Croghan, Samer Chmait, Rod Cupples, Elizabeth Galbreath, Joan Helmering, Fang-Tsao Hong, Steven R. Jordan, Roxanne K. Kunz, Robert J. M. Kurzeja, Longbin Liu, Klaus Michelsen, Nobuko Nishimura, Lewis D. Pennington, Steve F. Poon, Darren Reid, Glenn Sivits, Markian M. Stec, Nuria Tamayo, Seifu Tadesse, Gwyneth Van, Steve L. Vonderfecht, Robert C. Wahl, Kevin Yang, Jiandong Zhang, David J. Lloyd, Clarence Hale, Christopher Fotsch, and David J. St. Jean, Jr. "The Discovery of Potent Small Molecule GK-GKRP Disruptors for the Treatment of Diabetes" Presented at 6th International Conference on Drug Discovery and Therapy in Dubai, UAE February 10, **2014** (Invited Speaker).

84. Yang, Kevin C.; Nishimura, Nobuko; Norman, Mark H.; Liu, Longbin; Ashton, Kate S.; Bartberger, Michael D.; Chmait, Samer; Chen, Jie; Cupples, Rod; Fotsch, Christopher; Roxanne K. Kunz, Steve F. Poon, Glenn Sivits, Joan Helmering, David J. Lloyd, Clarence Hale, and David J. St. Jean, Jr. "Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-aryl-piperazine series of GK-GKRP disruptors" From Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, **2014**.

85. Tadesse, Seifu; Norman, Mark H.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Fotsch, Christopher; Hong, Fang-Tsao; Jordan, Steve R.; David J. Lloyd, Seifu Tadesse, Clarence Hale, and David J. St. Jean, Jr. "Optimization of a series of an N-arylsulfonamido-N'-aryl-piperazine GK-GKRP modulators: Exploration of a novel binding pocket in GKRP" Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, **2014**.


86. Longbin Liu, Mark H. Norman, Kate S. Ashton, Kristin L. Andrews, Marion C. Bryan, Michael D. Bartberger, Jie Chen, Kui Chen, Michelle Chen, Michael Croghan, Samer Chmait, Rod Cupples, Elizabeth Galbreath, Joan Helmering, Fang-Tsao Hong, Steven R. Jordan, Roxanne K. Kunz, Robert J. M. Kurzeja, , Klaus Michelsen, Nobuko Nishimura, Lewis D. Pennington, Steve F. Poon, Darren Reid, Glenn Sivits, Markian M. Stec, Nuria Tamayo, Seifu Tadesse, Gwyneth Van, Steve L. Vonderfecht, Robert C. Wahl, Kevin Yang, Jiandong Zhang, David J. Lloyd, Clarence Hale, Christopher Fotsch, and David J. St. Jean, Jr. “Small molecule disruptors of the GK-GKRP interaction as potential antidiabetics” From Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, **2014**.

87. Daniel B. Horne, Holger Monenschein, Nuria A. Tamayo, Michael D. Bartberger, Yunxin Bo, Jeffrey Clarine, Carl D. Davis, Vijay K. Gore, Matthew R. Kaller, Sonya G. Lehto, Vu V. Ma, Nobuko Nishimura, Thomas T. Nguyen, Phi Tang, Weiya Wang, Beth D. Youngblood, Maosheng Zhang, Mark H. Norman, and Narendra R. Gavva “Discovery, Optimization, and SAR of a Novel Series of Tetrahydroisoquinoline Transient Receptor Melastatin 8 (TRPM8) Antagonists” Presented at the 34th National Medicinal Chemistry Symposium, Charleston, South Carolina, May 18-21, **2014**.

88. Fang-Tsao Hong, Mark H. Norman, Kate S. Ashton, Michael D. Bartberger, Jie Chen, Samer Chmait, Rod Cupples, Christopher Fotsch, Steven R. Jordan, David J. Lloyd, Longbin Liu, Roxanne K. Kunz, Klaus Michelsen, Nobuko Nishimura, Lewis D. Pennington, Steve F. Poon, Darren Reid, Glenn Sivits, Markian M. Stec, Seifu Tadesse, Nuria Tamayo, Gwyneth Van, Kevin C. Yang, Jiandong Zhang, Clarence Hale, and David J. St. Jean, Jr. “Potent Small-Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Interaction as Potential Antidiabetic Agents” Presented at Mastering Medicinal Chemistry Conference, Boston MA, June 15, **2014**.

89. Siegmund, Aaron C.; Bourbeau, Matthew; St Jean, David J.; Bartberger, Michael D.; Pennington, Lewis D.; Norman, Mark H.; Hungate, Randy; Lloyd, David J.; Hale, Clarence “Small molecule inhibitors for glucokinase-glucokinase regulatory protein (GK-GKRP) binding: Optimization for in vivo target assessment of type II diabetes” From Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, **2014**.

PATENTS / INVENTIONS



1. Norman, Mark Henry; Navas, Frank, III. “Piperazine and piperidine derivatives and their use as antipsychotics” PCT Int. Appl. (1993), 204 pp. WO 9316073 A1 19930819.
2. Norman, Mark Henry; Navas, Frank, III. “Preparation of [(benzisothiazolyl)piperazinyl]butylpyridinecarboxamides and related compounds as antipsychotics” PCT Int. Appl. (1994), 59 pp. WO 9418196 A1 19940818.
3. Gerritz, Samuel; Norman, Mark H. “Crown Handling Devices” resulting in a 'Disclosure of Trade Secrets' agreement between Glaxo Wellcome and Chiron Technologies, April 24, 1998.
4. Norman, Mark H.; Chen, Ning; Han, Nianhe; Liu, Longbin; Hurt, Clarence R.; Fotsch, Christopher H.; Jenkins, Tracy J.; Moreno, Ofir A. “Preparation of bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists” PCT Int. Appl. (1999), 469 pp. WO 9940091 A1 19990812.
5. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Steiner, Joseph P. “Preparation of urea and carbamate derivatives of N-heterocyclic carboxylic acids and carboxylic acid isosteres for the treatment of neurodegenerative diseases and alopecia” PCT Int. Appl. (1999), 102 pp. WO 9962879 A1 19991209.
6. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian. “N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres for treatment of neurological disorders and alopecia” PCT Int. Appl. (1999), 96 pp. WO 9962880 A1 19991209.

7. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Steiner, Joseph P. "Preparation of aza-heterocyclic compounds used to treat neurological disorders and hair loss" PCT Int. Appl. (1999), 96 pp. 9962881 A1 19991209.
8. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Li, Jia-He; Steiner, Joseph P. "Aza-heterocyclic compounds used to treat neurological disorders and hair loss" PCT Int. Appl. (1999), 106 pp. WO 9962888 A1 19991209.
9. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-qian. "Preparation of prolinylalkanediones and related compounds for treating neurological disease, vision disorders, and alopecia" PCT Int. Appl. (2000), 166 pp. WO 2000032588 A2 20000608.
10. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian. "Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds, preparation thereof, and use in the treatment of neurological and other disorders" U.S. (2001), 62 pp., Cont.-in-part of U.S. Ser. No. 204,237, US 6331537 B1 20011218.
11. Burgess, Laurence E.; Gaudino, John; Groneberg, Robert D.; Norman, Mark H.; Rodriguez, Martha E.; Sun, Xicheng; Wallace, Eli M. "Preparation and use of α -arylsulfonylamino- α -benzylcarboxamides as phosphatase inhibitors" PCT Int. Appl. (2002), 77 pp. WO 2002004412 A2 20020117.
12. Santora, Vincent; Askew, Benny; Ghose, Arup; Hague, Andrew; Kim, Tae Seong; Laber, Ellen; Li, Aiwen; Lian, Brian; Liu, Gang; Norman, Mark Henry; Smith, Leon; Tasker, Andrew; Tegley, Christopher; Yang, Kevin. "Preparation of diheteroaryl ureas as antitumor agents" PCT Int. Appl. (2002), 371 pp. WO 2002014311 A2 20020221.
13. Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-qian. "Preparation of pyrrolidino and piperidino sulfonamides for treatment of neurological disorders and alopecia" U.S. Pat. Appl. Publ. (2002), 29 pp., Cont.-in-part of U. S. Provisional Ser. No. 87,842. US 2002052510 A1 20020502.
14. Fotsch, Christopher H.; Croghan, Michael; Doherty, Elizabeth M.; Kelly, Michael G.; Norman, Mark H.; Smith, Duncan M.; Tamayo, Nuria; Xi, Ning; Xu, Shimin. "Substituted piperidines as modulators of the melanocortin receptor" PCT Int. Appl. (2003), 239 pp. WO 2003009847 A1 20030206.
15. Fotsch, Christopher H.; Arasasingham, Premilla; Bo, Yunxin; Chen, Ning; Goldberg, Martin H.; Han, Nianhe; Hsieh, Feng-Yin; Kelly, Michael G.; Liu, Qingyian; Norman, Mark H.; Smith, Duncan M.; Stec, Markian; Tamayo, Nuria; Xi, Ning; Xu, Shimin. "Preparation of substituted piperazines as agonists of melanocortin receptors useful against obesity and diabetes" PCT Int. Appl. (2003), 331 pp. WO 2003009850 A1 20030206.
16. Bo, Yunxin Y.; Chakrabarti, Partha P.; Chen, Ning; Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Kelly, Michael G.; Liu, Qingyian; Norman, Mark Henry; Wang, Xianghong; Zhu, Jiawang; Ognyanov, Vassil; Bo, Yunxin Y.; Chakrabarti, Partha P.; Chen, Ning; Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Kelly, Michael; Liu, Qingyian; "Preparation of vanilloid receptor ligands and their use in treatments" PCT Int. Appl. (2003), 611 pp. WO 2003049702 A2 20030619.

17. Norman, Mark; Wang, Hui-Ling; Rzasa, Robert; Zhong, Wenge; Nguyen, Thomas; Kaller, Matthew. "Preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurological disorders and apoptosis" PCT Int. Appl. (2003), 490 pp. WO 2003066630 A2 20030814.
18. Huang, Qi; Kaller, Matthew; Nguyen, Thomas; Norman, Mark H.; Rzasa, Robert; Wang, Hui-Ling; Zhong, Wenge. "Preparation of 2-oxo-1,2,3,4-tetrahydroquinazolines as Cdk2 and Cdk5 kinase inhibitors for the treatment of cell proliferation-related disorders" PCT Int. Appl. (2003), 253 pp. WO 2003101985 A1 20031211.
19. Chakrabarti, Partha P.; Chen, Ning; Doherty, Elisabeth M.; Dominguez, Celia; Falsey, James Richard; Fotsch, Christopher H.; Hulme, Christopher; Katon, Jodie; Nixey, Thomas; Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H.; Rzasa, Robert Michael; Stec, Markian; Wang, Hui-ling; Zhu, Jiawang. "Preparation of (aryloxy)pyrimidine and (aryloxy)pyridazine as vanilloid receptor ligands" PCT Int. Appl. (2004), 340 pp. WO 2004014871 A1 20040219
20. Balan, Chenera; Bo, Yunxin; Dominguez, Celia; Fotsch, Christopher H.; Gore, Vijay K.; Ma, Vu Van; Norman, Mark H.; Ognyanov, Vassil I.; Qian, Yi-xin; Wang, Xianghong; Xi, Ning; Xu, Shimin. "Preparation of benzimidazoles as vanilloid receptor ligands" PCT Int. Appl. (2004), 259 pp. 2004035549 A1 20040429.
21. Zhong, Wenge; Norman, Mark Henry; Kaller, Matthew; Nguyen, Thomas; Rzasa, Robert Michael; Tegley, Christopher; Wang, Hui-Ling. "Preparation of 2-oxopyridin-3-yl thia(di)azoles as Cdk2 and Cdk5 kinase inhibitors for the treatment of cell proliferation-related disorders" PCT Int. Appl. (2004), 317 pp. WO 2004060890 A1 20040722.
22. Doherty, Elisabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate, Randall W.; Liu, Qingyan; Norman, Mark H.; Xi, Ning; Xu, Shimin. "A preparation of N-containing heterocyclic compounds, useful as vanilloid receptor ligands" U.S. Pat. Appl. Publ. (2004), 38 pp. US 2004157845 A1 20040812.
23. Chen, Ning; Nixey, Thomas; Norman, Mark H. "Preparation of pyridinyl and analogous vanilloid receptor ligands and their use in treating pain" PCT Int. Appl. (2005), 213 pp. CODEN: PIXXD2 WO 2005033105 A2 20050414.
24. Ncube, Mghele Vellah; Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H. "Preparation of N-(hetero)aryl 4-(pyridin-2-yl)benzamides as vanilloid receptor ligands" U.S. Pat. Appl. Publ. (2005), 25 pp. US 2005165015 A1 20050728.
25. Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H. "Preparation of N-heteroaryl substituted benzamides as vanilloid receptor ligands" U.S. Pat. Appl. Publ. (2005), 23 pp US 2005165028 A1 20050728.
26. Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H. "Preparation of substituted quinazolines and pyridopyrimidines as vanilloid receptor ligands" U.S. Pat. Appl. Publ. (2005), 22 pp. US 2005165032 A1 20050728.

27. Hulme, Christopher; Ncube, Mghele Vellah; Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H.; Wang, Xianghong; Zhu, Jiawang. “Preparation of substituted (hetero)aryl amides as vanilloid receptor ligands” U.S. Pat. Appl. Publ. (2005), 24 pp. US 2005165046 A1 20050728.
28. Hulme, Christopher; Ncube, Mghele Vellah; Norman, Mark H.; Ognyanov, Vassil I.; Pettus, Liping H.; Wang, Xianghong; Zhu, Jiawang. “Preparation of carboxamide derivatives as vanilloid receptor ligands and their use in treating pain” U.S. Pat. Appl. Publ. (2005), 34 pp. US 2005165049 A1 20050728.
29. Wang, Hui-Ling; Balan, Chenera; Doherty, Elizabeth M.; Falsey, James R.; Gore, Vijay Keshav; Katon, Jodie; Norman, Mark H. “Preparation of 4-heteroaryloxy-6-piperazinopyrimidines as vanilloid receptor ligands” U.S. Pat. Appl. Publ. (2005), 46 pp. US 2005176726 A1 20050811.
30. Balan, Chenera; Chen, Ning; Doherty, Elizabeth M.; Gore, Vijay Keshav; Norman, Mark H.; Wang, Hui-Ling. “Preparation of 4-heteroaryloxy-6-piperazinopyrimidines and 2-heteroaryloxy-4-piperazinopyrimidines as vanilloid receptor ligands” U.S. Pat. Appl. Publ. (2005), 64 pp. US 2005182067 A1 20050818.
31. Norman, Mark H.; Pettus, Liping H.; Wang, Xianghong; Zhu, Jiawang. “Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands” U.S. Pat. Appl. Publ. (2006), 96 pp. US 2006058308 A1 20060316.
32. Gore, Vijay Keshav; Ma, Vu Van; Norman, Mark H.; Ognyanov, Vassil I.; Xi, Ning. “Preparation of imidazolylpyridinylpiperazines as vanilloid receptor ligands for treatment of pain” U.S. Pat. Appl. Publ. (2006), 53 pp. US 2006084640 A1 20060420.
33. Norman, Mark H.; Ognyanov, Vassil I.; Rzasa, Robert M. “Preparation of substituted nitrogen-containing heterocycles as vanilloid receptor ligands for treating various diseases” U.S. Pat. Appl. Publ. (2006), 34 pp. US 2006089360 A1 20060427.
34. Norman, Mark H.; Ognyanov, Vassil I.; Wang, Xianghong. “Preparation of substituted benzimidazoles as vanilloid receptor ligands and their use in treatments” U.S. Pat. Appl. Publ. (2006), 25 pp. US 2006160872 A1 20060720.
35. Bo, Yunxin Y.; Chakrabarti, Partha P.; Chen, Ning; Liao, Hongyu; Norman, Mark H.; Stec, Markian; Tamayo, Nuria; Wang, Xianghong. “Preparation of heterocyclic vanilloid receptor ligands and their use in treatment of pain, inflammation and other disorders” U.S. Pat. Appl. Publ. (2006), 88pp. US 2006183745 A1 20060817.
36. Doherty, Elizabeth M.; Liao, Hongyu; Norman, Mark H.; Retz, Daniel M. “Aminopyrimidine derivatives as vanilloid receptor ligands and their preparation, pharmaceutical compositions and use in treatment of various diseases” U.S. Pat. Appl. Publ. (2006), 55pp. US 2006235036 A1 20061019.

37. Doherty, Elizabeth M.; Katon, Jodie; Norman, Mark H.; Retz, Daniel M.; Wang, Xianghong; Bo, Yunxin Y.; Tamayo, Nuria; Nishimura, Nobuko; Liao, Hongyu. “Aminopyrimidine derivatives as vanilloid receptor ligands and their preparation, pharmaceutical compositions and use in treatment of various diseases” U.S. Pat. Appl. Publ. (2006), 90pp. US 2006241296 A1 20061026.

38. Kim, Tae-Seong; Bauer, David; Bellon, Steven; Boezio, Alessandro; Booker, Shon; Choquette, Deborah; D'Amico, Derin C.; D'Angelo, Noel; Dominguez, Celia; Fellows, Ingrid M.; Germain, Julie; Graceffa, Russell; Harmange, Jean-Christophe; Hirai, Satoko; La, Daniel; Lee, Matthew; Liu, Longbin; Norman, Mark H.; Potashman, Michele; Roveto, Philip; Siegmund, Aaron C.; Xi, Ning; Yang, Kevin. “Substituted cyclic amide derivatives as protein kinase inhibitors for treating hepatocyte growth factor (HGF)-related diseases” PCT Int. Appl. (2006), 281pp. WO 2006116713 A1 20061102.

39. Chen, Ning; Nishimura, Nobuko; Norman, Mark H.; Ognyanov, Vassil I. “Vanilloid receptor ligands and their use in treatments” U.S. Pat. Appl. Publ. (2007), 51pp. US 2007149513 A1 20070628.

40. Albrecht, Brian; Bauer, David; Bellon, Steven; Bode, Christiane; Booker, Shon; Boezio, Alessandro; Choquette, Deborah; D'Amico, Derin; Harmange, Jean-Christophe; Hirai, Satoko; Hungate, Randall; Kim, Tae-Seong; Lewis, Richard; Liu, Longbin; Lohman, Julia; Norman, Mark; Potashman, Michele; Siegmund, Aaron; Springer, Stephanie; Stec, Markian; Xi, Ning; Yang, Kevin. “Preparation of fused heterocyclic derivatives for treating HGF mediated diseases” PCT Int. Appl. (2008), 310 pp. WO 2008008539 A2 20080117.

41. Bellon, Steven; Booker, Shon; D'Angelo, Noel; Germain, Julie; Harmange, Jean-Christophe; Kim, Tae-Seong; Lee, Matthew; Liu, Longbin; Norman, Mark H.; Rainbeau, Elizabeth; Xi, Ning; Xu, Shimin. “Preparation of substituted heterocycles for preventing and treating HGF mediated diseases” PCT Int. Appl. (2008), 93pp. WO 2008079294 A1 20080703.

42. Bellon, Steven; Booker, Shon; D'Angelo, Noel; Fellows, Ingrid M.; Harmange, Jean-Christophe; Kim, Tae-Seong; Lee, Matthew; Liu, Longbin; Norman, Mark H. “Preparation of substituted heterocycles for preventing and treating c-Met mediated diseases” PCT Int. Appl. (2008), 89pp. WO 2008079291 A2 20080703.

43. Albrecht, Brian K.; Bellon, Steven; Booker, Shon; Cheng, Alan C.; D'Amico, Derin; D'Angelo, Noel; Harmange, Jean-Christophe; Kim, Tae-Seong; Liu, Longbin; Norman, Mark H.; Siegmund, Aaron C.; Stec, Markian; Xi, Ning; Yang, Kevin. “Nitrogen-containing heterocyclyl ketones as HGF inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases” PCT Int. Appl. (2008), 238pp. WO 2008103277 A2 20080828.

44. Booker, Shon; D'Angelo, Noel; D'Amico, Derin C.; Kim, Tae-Seong; Liu, Longbin; Meagher, Kristin; Norman, Mark H.; Panter, Kathleen; Schenkel, Laurie B.; Smith, Adrian L.; Tamayo, Nuria A.; Whittington, Douglas A.; Xi, Ning; Yang, Kevin. “Preparation of 2-aminobenzothiazole derivatives as phosphoinositide 3-kinase (PI3 kinase) modulators” PCT Int. Appl. (2009), 279pp. WO 2009017822.

45. Nishimura, Nobuko; Norman, Mark H.; Tamayo, Nuria; Tang, Phi; Bo, Yunxin “Preparation of condensed piperidine derivatives useful as therapeutic vanilloid receptor ligands” PCT Int. Appl. (2009), 113pp. WO 2009038812 A1 20090326.

46. Albrecht, Brian K.; Bauer, David; Bellon, Steven; Bode, Christiane M.; Booker, Shon; Boezio, Alessandro; Choquette, Deborah; D'Amico, Derin; Harmange, Jean-Christophe; Hirai, Satoko; Hungate, Randall W.; Kim, Tae-Seong; Lewis, Richard T.; Liu, Longbin; Lohman, Julia; Norman, Mark H.; Potashman, Michele; Siegmund, Aaron C.; Springer, Stephanie; Stec, Markian; Xi, Ning; Yang, Kevin. “Fused heterocyclic derivatives as HGF modulators and their preparation and methods of use” U.S. Pat. Appl. Publ. (2009), 252pp., Cont.-in-part of U.S. Ser. No. 879,034. US 2009124609 A1 20090514.

47. Norman, Mark H.; Bo, Yunxin Y.; Gore, Vijay Keshav; Horne, Daniel; Kaller, Matthew; Ma, Vu Van; Monenschein, Holger; Nguyen, Thomas; Nishimura, Nobuko; Tamayo, Nuria. “Preparation of substituted dihydroisoquinoline derivatives for use as TRP-M8 receptor ligands” PCT Int. Appl. (2009), 185pp. WO 2009073203 A1 20090611.

48. Booker, Shon; Kim, Tae-Seong; Liao, Hongyu; Liu, Longbin; Norman, Mark H.; Peterson, Emily Anne; Stec, Markian; Tamayo, Nuria A. “Inhibitors of PI3 Kinase” U.S. Pat. Appl. Publ. (2009), 66pp. US 2009163489 A1 20090625.

49. Albrecht, Brian K.; Bauer, David; Bellon, Steven; Bode, Christiane M.; Booker, Shon; Boezio, Alessandro; Choquette, Deborah; D'Amico, Erin; Harmange, Jean-Christophe; Hirai, Satoko; Hungate, Randall W.; Kim, Tae-Seong; Lewis, Richard T.; Liu, Longbin; Lohman, Julia; Norman, Mark H.; Potashman, Michelle; Siegmund, Aaron C.; Springer, Stephanie; Stec, Markian; Xi, Ning; Yang, Kevin; Peterson, Emily A.; Romero, Karina; Copeland, Katrina W. “Fused heterocyclic derivatives as HGF modulators and their preparation and methods of use” PCT Int. Appl. (2009), 236pp. WO 2009091374 A2 20090723.

50. Bo, Yunxin Y.; Booker, Shon; Bryan, Marian; Deak, Holly L.; Liu, Longbin; Andrews, Kristin; Nishimura, Nobuko; Norman, Mark H.; Panter, Kathleen; Schenkel, Laurie; Siegmund, Aaron C.; Tamayo, Nuria A.; Yang, Kevin. “Heteroarylpyridine derivatives as inhibitors of PI3 kinase and their preparation and use in the treatment of cancer” PCT Int. Appl. (2009), 213pp. WO 2009155121 A2 20091223.

51. Albrecht, Brian K.; Bauer, David; Bellon, Steven; Bode, Christiane M.; Booker, Shon; Boezio, Alessandro; Choquette, Deborah; D'Amico, Derin; Harmange, Jean-Christophe; Hirai, Satoko; et al Fused heterocyclic derivatives as HGF modulators and their preparation and methods of use U.S. Pat. Appl. Publ. (2009), US 20090318436 A1 20091224.

52. Bo, Yunxin Y.; Liu, Longbin; Nishimura, Nobuko; Norman, Mark H.; Siegmund, Aaron C.; Tamayo, Nuria A.; Yang, Kevin. “Preparation of substituted imidazopyridines and their analogs as inhibitors of PI3 kinase” PCT Int. Appl. (2010), 100pp. WO 2010108074 A2 20100923.

53. Andrews, Kristin; Bo, Yunxin Y.; Booker, Shon; Cee, Victor J.; D'Angelo, Noel; Herberich, Bradley J.; Hong, Fang-Tsao; Jackson, Claire L. M.; Lanman, Brian A.; Liao, Hongyu; Liu, Longbin; Nishimura, Nobuko; Norman, Mark H.; Pettus, Liping H.; Reed, Anthony B.; Smith, Adrian L.; Tadesse, Seifu; Tamayo, Nuria A.; Wu, Bin; Wurz, Ryan; Yang, Kevin. "Preparation of 3-azaheterocyclyl-N-(substituted monocyclyl or bicyclyl)pyridine-2-amines and analogs as PI3 kinase and/or mTOR inhibitors for treating cancers" U.S. Pat. Appl. Publ. (2010), 266pp. US 20100273764 A1 20101028.

54. Bode, Christiane; Boezio, Alessandro; Cheng, Alan C.; Choquette, Deborah; Coats, James R.; Copeland, Katrina W.; Huang, Hongbing; La, Daniel; Lewis, Richard; Liao, Hongyu; Potashman, Michele; Stellwagen, John; Yi, Shuyan; Norman, Mark; Stec, Markian; Peterson, Emily A.; Graceffa, Russell. "Preparation of heteroaryl compounds as PIKK inhibitors for the treatment of cancer" PCT Int. Appl. (2010), 174pp. WO 2010132598 A1 20101118.

55. Ashton, Kate; Bartberger, Michael David; Bo, Yunxin; Bryan, Marian C.; Croghan, Michael; Fotsch, Christopher Harold; Hale, Clarence Henderson; Kunz, Roxanne Kay; Liu, Longbin; Nishimura, Nobuko; Norman, Mark H.; Pennington, Lewis Dale; Poon, Steve Fong; Stec, Markian Myroslaw; St. Jean, David Joseph, Jr.; Tamayo, Nuria A.; Tegley, Christopher Michael; Yang, Kevin Chao. "Preparation of sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes and other diseases" PCT Int. Appl. (2012), 667pp. WO 2012027261 A1 20120301.

56. Bartberger, Michael D.; Croghan, Michael D.; Fotsch, Christopher H.; Norman, Mark H.; Pennington, Lewis D.; Reichelt, Andreas; St. Jean, David J., Jr.; Tegley, Christopher M. "Preparation of benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes" PCT Int. Appl. (2012), WO 2012138776 A1 20121011.

57. Ashton, Kate; Bourbeau, Matthew Paul; Hong, Fang-Tsao; Liu, Longbin; Nishimura, Nobuko; Norman, Mark H.; Poon, Steve F.; Stec, Markian M.; St. Jean, David J., Jr.; Tamayo, Nuria A.; Yang, Kevin C. "Preparation of cyclic sulfonyl compounds that interact with glucokinase regulatory protein for use in treating type 2 diabetes and other diseases" PCT Int. Appl. (2013), WO 2013123444 A1 20130822.

58. Cee, Victor; Chavez, Frank, Jr.; Chen, Jian J.; Harrington, Essa Hu; Herberich, Bradley; Jackson, Claire L. M.; Lanman, Brian A.; Nguyen, Thomas T.; Norman, Mark H.; Pettus, Liping H.; Reed, Anthony B.; Smith, Adrian L.; Tamayo, Nuria A.; Tasker, Andrew; Wang, Hui-Ling; Wu, Bin; Wurz, Ryan "Preparation of fused pyridinones and related compounds as Pim kinase inhibitors and their use in the treatment of cancer" PCT Int. Appl. (2013), WO 2013130660 A1 20130906.

59. Ashton, Kate; Bartberger, Michael D.; Bourbeau, Matthew Paul; Croghan, Michael D.; Fotsch, Christopher H.; Hungate, Randall W.; Kong, Ke; Nishimura, Nobuko; Norman, Mark H.; Pennington, Lewis D.; et al "Preparation of benzothiophene sulfonamides and related compound that interact with glucokinase regulatory protein" PCT Int. Appl. (2013), WO 2013173382 A1 20131121.

60. Ashton, Kate; Fotsch, Christopher H.; Kunz, Roxanne K.; Liu, Longbin; Nishimura, Nobuko; Norman, Mark H.; Siegmund, Aaron C.; St. Jean, David J., Jr.; Tamayo, Nuria A.; Yang, Kevin C. “Preparation of N-(arylsulfonyl)alkynylpiperazine derivatives that interact with glucokinase regulatory protein” PCT Int. Appl. (2014), WO 2014035872 A1 20140306.

61. Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Shon Booker, Alessandro Boezio, Deborah Choquette, Derin D'Amico, Jean-Christophe Harmange, Satoko Hirai, Randall W. Hungate, Tae-Seong Kim, Richard T. Lewis, Longbin Liu, Julia W. Lohman, Mark H. Norman, Michele Potashman, Aaron C. Siegmund, Stephanie K. Springer, Markian Stec, Ning Xi, Kevin Yang “Fused heterocyclic derivatives and methods of use” U.S. Pat. Appl. Publ. (2015), US 20159066954.

62. Victor Cee, Frank Chavez, Jr., Jian J. Chen, Essa Hu Harrington, Bradley Herberich, Claire L.m. Jackson, Brian A. Lanman, Thomas T. Nguyen, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Nuria A. Tamayo, Andrew Tasker, Hui-ling Wang, Bin Wu, Ryan Wurz “Amides as PIM Inhibitors” (2016), US 9394297.

63. Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, James A. Brown, Jian J. Chen, Yuan Cheng, Michael J. Frohn, Angel Guzman-Perez, Paul E. Harrington, Longbin Liu, Qingyian Liu, Jonathan D. Low, Vu Van Ma, James Manning, Ana Elena Minatti, Thomas T. Nguyen, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Alexander J. Pickrell, Wenyuan Qian, Shannon Rumfelt, Robert M. Rzasa, Aaron C. Siegmund, Markian M. Stec, Ryan D. White, Qiufen Xue “Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use” (2017), US 9550762.

64. Bai, Xiaoguang; Hong, Xinfu; Mark H. Norman; Qu, Qingxi; Zhou, Xiansi; Zhang, Rui; Zheng, Zhihui “METTL3 Inhibitory Compounds” PCT Int. Appl. (2023), WO 2023104209 A1 202306015.

65. Alexander Kamb, Mark H, Norman “Lipid Nanoparticles Targeting Immune Cells” (January 13, 2023), (A2 Bio application), 061250-552P01US.

66. Bai, Xiaoguang; Mark H. Norman; Hong, Xinfu; Zhang, Rui “METTL3 Inhibitory Compounds” (May 7, 2024), Chinese application number: CN117986247A.

67. Bai, Xiaoguang; Mark H. Norman; Hong, Xinfu; Zhang, Rui “METTL3 Inhibitors and Application Thereof” (July 19, 2024), Chinese application number: CN20241006166.8.